Minimally	O
modified	O
low	O
density	O
lipoprotein	B-protein
-induced	O
inflammatory	O
responses	O
in	O
endothelial	B-cell_type
cells	I-cell_type
are	O
mediated	O
by	O
cyclic	O
adenosine	O
monophosphate	O
.	O

We	O
have	O
previously	O
shown	O
that	O
minimally	B-cell_line
oxidized	I-cell_line
LDL	I-cell_line
(	I-cell_line
MM-LDL	I-cell_line
)	I-cell_line
activated	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
to	O
increase	O
their	O
interaction	O
with	O
monocytes	B-cell_type
but	O
not	O
neutrophils	B-cell_type
,	O
inducing	O
monocyte	O
but	O
not	O
neutrophil	O
binding	O
and	O
synthesis	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
and	O
monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
.	O

In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte-specific	O
response	O
is	O
induced	O
.	O

Both	O
induction	O
of	O
monocyte	O
binding	O
and	O
mRNA	O
levels	O
for	O
M-CSF	B-protein
by	O
MM-LDL	B-protein
were	O
not	O
inhibited	O
in	O
protein	O
kinase	O
C-depleted	O
endothelial	B-cell_type
cells	I-cell_type
.	O

A	O
number	O
of	O
our	O
studies	O
indicate	O
that	O
cAMP	O
is	O
the	O
second	O
messenger	O
for	O
the	O
effects	O
of	O
MM-LDL	B-protein
cited	O
above	O
.	O

Incubation	O
of	O
endothelial	B-cell_type
cells	I-cell_type
with	O
MM-LDL	B-protein
caused	O
a	O
173	O
%	O
increase	O
in	O
intracellular	O
cAMP	O
levels	O
.	O

Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM-LDL	B-protein
.	O

Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte-endothelial	O
interactions	O
.	O

Although	O
endothelial	B-RNA
leukocyte	I-RNA
adhesion	I-RNA
molecule	I-RNA
(	I-RNA
ELAM	I-RNA
)	I-RNA
mRNA	I-RNA
synthesis	O
can	O
be	O
regulated	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
ELAM	B-protein
was	O
not	O
expressed	O
and	O
ELAM	B-RNA
mRNA	I-RNA
was	O
only	O
slightly	O
elevated	O
in	O
response	O
to	O
MM-LDL	B-protein
.	O

We	O
present	O
evidence	O
that	O
induction	O
of	O
neutrophil	B-cell_type
binding	O
by	O
LPS	O
is	O
actually	O
suppressed	O
by	O
agents	O
that	O
elevated	O
cAMP	O
levels	O
.	O

Minimally	NULL
Modified	NULL
Low	NULL
Density	NULL
Lipoprotein-induced	NULL
Inflammatory	NULL
Responses	NULL
in	NULL
Endothelial	NULL
Cells	NULL
Are	NULL
Mediated	NULL
by	NULL
Cyclic	NULL
Adenosine	NULL
Monophosphate	NULL
Farhad	NULL
Parhami	NULL
,	NULL
*	NULL
Zhuang	NULL
T.	NULL
Fang	NULL
,	NULL
*	NULL
Alan	NULL
M.	NULL
Fogelman	NULL
,	NULL
*	NULL
Ali	NULL
Andalibi	NULL
,	NULL
*	NULL
Mary	NULL
C.	NULL
Territo	NULL
,	NULL
}	NULL
and	NULL
Judith	NULL
A.	NULL
Bertiner**	NULL
Departments	NULL
of	NULL
*	NULL
Pathology	NULL
and	NULL
*	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
California	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
90024-1732	NULL
Abstract	NULL
We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
minimally	NULL
oxidized	NULL
LDL	NULL
(	NULL
MM-LDL	NULL
)	NULL
activated	NULL
endothelial	NULL
cells	NULL
to	NULL
increase	NULL
their	NULL
interaction	NULL
with	NULL
monocytes	NULL
but	NULL
not	NULL
neutrophils	NULL
,	NULL
inducing	NULL
monocyte	NULL
but	NULL
not	NULL
neutrophil	NULL
binding	NULL
and	NULL
synthesis	NULL
of	NULL
monocyte	NULL
chemotactic	NULL
protein-1	NULL
and	NULL
monocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
M-CSF	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
studies	NULL
we	NULL
have	NULL
examined	NULL
the	NULL
signaling	NULL
pathways	NULL
by	NULL
which	NULL
this	NULL
monocyte-specific	NULL
response	NULL
is	NULL
induced	NULL
.	NULL

Both	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
and	NULL
mRNA	NULL
levels	NULL
for	NULL
M-CSF	NULL
by	NULL
MM-LDL	NULL
were	NULL
not	NULL
inhibited	NULL
in	NULL
protein	NULL
kinase	NULL
C-de-pleted	NULL
endothelial	NULL
cells	NULL
.	NULL

A	NULL
number	NULL
of	NULL
our	NULL
studies	NULL
indicate	NULL
that	NULL
cAMP	NULL
is	NULL
the	NULL
second	NULL
messenger	NULL
for	NULL
the	NULL
effects	NULL
of	NULL
MM-LDL	NULL
cited	NULL
above	NULL
.	NULL

Incubation	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
MM-LDL	NULL
caused	NULL
a	NULL
173	NULL
%	NULL
increase	NULL
in	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
.	NULL

Agents	NULL
which	NULL
increased	NULL
cAMP	NULL
levels	NULL
,	NULL
including	NULL
cholera	NULL
toxin	NULL
,	NULL
pertussis	NULL
toxin	NULL
,	NULL
dibutyryl	NULL
cAMP	NULL
,	NULL
and	NULL
isoproterenol	NULL
mimicked	NULL
the	NULL
actions	NULL
of	NULL
MM-LDL	NULL
.	NULL

Agents	NULL
which	NULL
elevated	NULL
cAMP	NULL
were	NULL
also	NULL
shown	NULL
to	NULL
activate	NULL
NFxB	NULL
,	NULL
suggesting	NULL
a	NULL
role	NULL
for	NULL
this	NULL
transcription	NULL
factor	NULL
in	NULL
activation	NULL
of	NULL
monocyte-endothelial	NULL
interactions	NULL
.	NULL

Although	NULL
endothelial	NULL
leukocyte	NULL
adhesion	NULL
molecule	NULL
(	NULL
ELAM	NULL
)	NULL
mRNA	NULL
synthesis	NULL
can	NULL
be	NULL
regulated	NULL
by	NULL
NFxB	NULL
,	NULL
ELAM	NULL
was	NULL
not	NULL
expressed	NULL
and	NULL
ELAM	NULL
mRNA	NULL
was	NULL
only	NULL
slightly	NULL
elevated	NULL
in	NULL
response	NULL
to	NULL
MM-LDL	NULL
.	NULL

We	NULL
present	NULL
evidence	NULL
that	NULL
induction	NULL
of	NULL
neutrophil	NULL
binding	NULL
by	NULL
LPS	NULL
is	NULL
actually	NULL
suppressed	NULL
by	NULL
agents	NULL
that	NULL
elevated	NULL
cAMP	NULL
levels	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1993	NULL
.	NULL

92:471-478	NULL
.	NULL
)	NULL

Key	NULL
words	NULL
:	NULL
atherosclerosis	NULL
«	NULL
MM-LDL	NULL
+	NULL
cAMP	NULL
«	NULL
inflammation	NULL
«	NULL
monocyte	NULL
binding	NULL
Introduction	NULL
Activation	NULL
of	NULL
endothelial	NULL
cells	NULL
to	NULL
synthesize	NULL
binding	NULL
molecules	NULL
and	NULL
chemotactic	NULL
factors	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
elicit	NULL
increased	NULL
interaction	NULL
with	NULL
leukocytes	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

An	NULL
important	NULL
early	NULL
event	NULL
in	NULL
the	NULL
initiation	NULL
of	NULL
atherosclerosis	NULL
is	NULL
the	NULL
increased	NULL
interaction	NULL
of	NULL
monocytes	NULL
with	NULL
endothelial	NULL
cells	NULL
lining	NULL
the	NULL
vessel	NULL
wall	NULL
(	NULL
4	NULL
)	NULL
.	NULL

In	NULL
animals	NULL
fed	NULL
a	NULL
high	NULL
cholesterol	NULL
diet	NULL
,	NULL
monocytes	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
more	NULL
avidly	NULL
to	NULL
the	NULL
endothelium	NULL
,	NULL
transmigrate	NULL
through	NULL
endothelial	NULL
cell	NULL
junctions	NULL
,	NULL
and	NULL
enter	NULL
the	NULL
intimal	NULL
space	NULL
where	NULL
they	NULL
mature	NULL
and	NULL
form	NULL
macrophages	NULL
(	NULL
5	NULL
)	NULL
.	NULL

These	NULL
macrophages	NULL
accumulate	NULL
lipids	NULL
and	NULL
contribute	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
fatty	NULL
streak	NULL
.	NULL

Address	NULL
reprint	NULL
requests	NULL
to	NULL
Farhad	NULL
Parhami	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
UCLA	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Center	NULL
for	NULL
the	NULL
Health	NULL
Sciences	NULL
,	NULL
10833	NULL
Le-Conte	NULL
Avenue	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
90024-1732	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
30	NULL
October	NULL
1992	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
19	NULL
February	NULL
1993	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
0021-97	NULL
$	NULL
2.00	NULL
Volume	NULL
92	NULL
,	NULL
July	NULL
1993	NULL
,	NULL
471-478	NULL
Since	NULL
oxidized	NULL
lipids	NULL
have	NULL
been	NULL
found	NULL
in	NULL
fatty	NULL
streak	NULL
lesions	NULL
(	NULL
6	NULL
)	NULL
and	NULL
experiments	NULL
with	NULL
antioxidants	NULL
have	NULL
shown	NULL
reduced	NULL
lesion	NULL
formation	NULL
(	NULL
7	NULL
)	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
these	NULL
lipids	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
atherogenesis	NULL
.	NULL

Our	NULL
group	NULL
has	NULL
shown	NULL
that	NULL
treatment	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
minimally	NULL
oxidized	NULL
(	NULL
modified	NULL
)	NULL
LDL	NULL
(	NULL
MM-LDL	NULL
)	NULL
'	NULL
but	NULL
not	NULL
native	NULL
LDL	NULL
caused	NULL
an	NULL
increase	NULL
in	NULL
monocyte	NULL
but	NULL
not	NULL
neutrophil	NULL
binding	NULL
and	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
production	NULL
of	NULL
monocyte	NULL
chemotactic	NULL
protein-1	NULL
(	NULL
MCP-1	NULL
)	NULL
and	NULL
monocyte	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
M-CSF	NULL
)	NULL
mRNA	NULL
and	NULL
protein	NULL
(	NULL
8-10	NULL
)	NULL
.	NULL

However	NULL
no	NULL
neutrophil	NULL
chemotactic	NULL
factor	NULL
could	NULL
be	NULL
detected	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
studies	NULL
showed	NULL
that	NULL
injection	NULL
of	NULL
MM-LDL	NULL
but	NULL
not	NULL
highly	NULL
oxidized	NULL
LDL	NULL
into	NULL
mice	NULL
induced	NULL
increases	NULL
in	NULL
mRNA	NULL
for	NULL
MCP-1	NULL
and	NULL
M-CSF	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Increased	NULL
levels	NULL
of	NULL
mRNA	NULL
for	NULL
MCP-1	NULL
and	NULL
M-CSF	NULL
have	NULL
been	NULL
found	NULL
in	NULL
human	NULL
fatty	NULL
streak	NULL
lesions	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

MCP-1	NULL
is	NULL
a	NULL
highly	NULL
active	NULL
monocyte	NULL
chemotactic	NULL
factor	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Proliferation	NULL
and	NULL
survival	NULL
of	NULL
monocytes	NULL
and	NULL
macrophages	NULL
in	NULL
the	NULL
lesion	NULL
may	NULL
be	NULL
supported	NULL
by	NULL
the	NULL
local	NULL
production	NULL
of	NULL
M-CSF	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
inflammatory	NULL
mediators	NULL
that	NULL
have	NULL
been	NULL
tested	NULL
,	NULL
including	NULL
LPS	NULL
,	NULL
thrombin	NULL
,	NULL
IL-1	NULL
,	NULL
and	NULL
TNF	NULL
(	NULL
16-19	NULL
)	NULL
,	NULL
MM-LDL	NULL
is	NULL
the	NULL
only	NULL
one	NULL
shown	NULL
to	NULL
induce	NULL
monocyte	NULL
but	NULL
not	NULL
neutrophil	NULL
interaction	NULL
with	NULL
the	NULL
endothelium	NULL
.	NULL

Understanding	NULL
of	NULL
the	NULL
signaling	NULL
molecules	NULL
involved	NULL
in	NULL
the	NULL
actions	NULL
of	NULL
MM-LDL	NULL
is	NULL
important	NULL
since	NULL
they	NULL
also	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
other	NULL
chronic	NULL
inflammatory	NULL
processes	NULL
in	NULL
vivo	NULL
,	NULL
characterized	NULL
predominantly	NULL
by	NULL
monocytic	NULL
infiltration	NULL
.	NULL

To	NULL
elucidate	NULL
the	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
MM-LDL	NULL
,	NULL
we	NULL
explored	NULL
the	NULL
signaling	NULL
pathways	NULL
by	NULL
which	NULL
it	NULL
activates	NULL
the	NULL
endothelium	NULL
.	NULL

Two	NULL
major	NULL
second	NULL
messengers	NULL
that	NULL
have	NULL
been	NULL
extensively	NULL
studied	NULL
are	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
and	NULL
cAMP	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
both	NULL
pathways	NULL
in	NULL
whole	NULL
cells	NULL
is	NULL
mainly	NULL
receptor	NULL
mediated	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

PKC	NULL
is	NULL
a	NULL
family	NULL
of	NULL
closely	NULL
related	NULL
proteins	NULL
that	NULL
differ	NULL
in	NULL
substrate	NULL
specificity	NULL
,	NULL
co-factor	NULL
dependency	NULL
,	NULL
and	NULL
tissue	NULL
distribution	NULL
(	NULL
21	NULL
)	NULL
.	NULL

It	NULL
exists	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
cells	NULL
and	NULL
is	NULL
generally	NULL
activated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
calcium	NULL
and	NULL
diacylglycerol	NULL
.	NULL

Phorbol	NULL
esters	NULL
such	NULL
as	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
are	NULL
known	NULL
to	NULL
induce	NULL
cellular	NULL
responses	NULL
by	NULL
directly	NULL
activating	NULL
PKC	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Agonist-induced	NULL
cellular	NULL
responses	NULL
caused	NULL
by	NULL
PKC	NULL
activation	NULL
are	NULL
down-regulated	NULL
by	NULL
pretreatment	NULL
of	NULL
cells	NULL
with	NULL
phorbol	NULL
esters	NULL
for	NULL
24-48	NULL
h	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
adenylate	NULL
cyclase	NULL
and/or	NULL
cAMP	NULL
phosphodiesterase	NULL
determines	NULL
the	NULL
levels	NULL
of	NULL
intracellular	NULL
cAMP	NULL
(	NULL
20	NULL
)	NULL
and	NULL
,	NULL
consequently	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
(	NULL
PKA	NULL
)	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
adenylate	NULL
cyclase	NULL
is	NULL
1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CS	NULL
,	NULL
calf	NULL
serum	NULL
;	NULL
CT	NULL
,	NULL
cholera	NULL
toxin	NULL
;	NULL
dbcAMP	NULL
,	NULL
dibutyryl	NULL
cAMP	NULL
;	NULL
ELAM	NULL
,	NULL
endothelial	NULL
leukocyte	NULL
adhesion	NULL
molecule	NULL
;	NULL
G	NULL
;	NULL
,	NULL
inhibitory	NULL
G	NULL
protein	NULL
;	NULL
G	NULL
,	NULL
excitatory	NULL
G	NULL
protein	NULL
;	NULL
IBMX	NULL
,	NULL
3-isobutyl-	NULL
!	NULL

-methylxanthine	NULL
;	NULL
IP	NULL
,	NULL
isoproterenol	NULL
;	NULL
LPC	NULL
,	NULL
lysophosphati-dylcholine	NULL
;	NULL
MDA	NULL
,	NULL
malondialdehyde	NULL
;	NULL
MCP-1	NULL
,	NULL
monocyte	NULL
chemotactic	NULL
protein-1	NULL
;	NULL
M-CSF	NULL
,	NULL
monocyte	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
MM-LDL	NULL
,	NULL
minimally	NULL
modified	NULL
LDL	NULL
;	NULL
PKA	NULL
,	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
PLA	NULL
;	NULL
,	NULL
phospholipase	NULL
A	NULL
;	NULL
;	NULL
PT	NULL
,	NULL
pertussis	NULL
toxin	NULL
;	NULL
RAEC	NULL
,	NULL
rabbit	NULL
aortic	NULL
endothelial	NULL
cells	NULL
;	NULL
SLO	NULL
,	NULL
soybean	NULL
lipoxygenase	NULL
.	NULL

MM-LDL~-induced	NULL
Inflammatory	NULL
Responses	NULL
Are	NULL
Mediated	NULL
by	NULL
cAMP	NULL
__	NULL
ATA	NULL
regulated	NULL
by	NULL
excitatory	NULL
(	NULL
G	NULL
,	NULL
)	NULL
and	NULL
inhibitory	NULL
(	NULL
G	NULL
;	NULL
)	NULL
G	NULL
proteins	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
G	NULL
proteins	NULL
in	NULL
mediating	NULL
cellular	NULL
responses	NULL
to	NULL
stimulators	NULL
has	NULL
been	NULL
extensively	NULL
reviewed	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Cholera	NULL
toxin	NULL
(	NULL
CT	NULL
)	NULL
activates	NULL
G	NULL
,	NULL
by	NULL
ADP-ribosylating	NULL
its	NULL
alpha	NULL
subunit	NULL
,	NULL
thus	NULL
inhibiting	NULL
its	NULL
GTPase	NULL
activity	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Pertussis	NULL
toxin	NULL
(	NULL
PT	NULL
)	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
inhibit	NULL
G	NULL
;	NULL
by	NULL
ADP-ribosylation	NULL
and	NULL
to	NULL
po-tentiate	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
stimulatory	NULL
arm	NULL
of	NULL
the	NULL
adenylate	NULL
cyclase	NULL
system	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Many	NULL
physiological	NULL
agonists	NULL
act	NULL
via	NULL
cell	NULL
surface	NULL
receptors	NULL
to	NULL
alter	NULL
adenylate	NULL
cyclase	NULL
activity	NULL
;	NULL
isoproterenol	NULL
(	NULL
IP	NULL
)	NULL
,	NULL
a	NULL
beta	NULL
adrenergic	NULL
receptor	NULL
agonist	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
elevate	NULL
cAMP	NULL
levels	NULL
in	NULL
endothelial	NULL
cells	NULL
by	NULL
activating	NULL
G	NULL
,	NULL
(	NULL
26	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
purified	NULL
PKC	NULL
and	NULL
isolated	NULL
preparations	NULL
of	NULL
adenylate	NULL
cyclase	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
activated	NULL
by	NULL
certain	NULL
native	NULL
and	NULL
oxidized	NULL
fatty	NULL
acids	NULL
as	NULL
well	NULL
as	NULL
products	NULL
of	NULL
lipid	NULL
peroxida-tion	NULL
(	NULL
27-29	NULL
)	NULL
,	NULL
which	NULL
may	NULL
be	NULL
present	NULL
in	NULL
MM-LDL	NULL
.	NULL

Also	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
alteration	NULL
of	NULL
membrane	NULL
physical	NULL
properties	NULL
by	NULL
changing	NULL
its	NULL
lipid	NULL
composition	NULL
affects	NULL
adenylate	NULL
cyclase	NULL
activity	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NF	NULL
«	NULL
B	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
gene	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
increased	NULL
PKC	NULL
or	NULL
PK	NULL
A	NULL
activity	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

This	NULL
transcription	NULL
factor	NULL
exists	NULL
as	NULL
a	NULL
cytosolic	NULL
dimer	NULL
bound	NULL
to	NULL
an	NULL
inhibitory	NULL
molecule	NULL
,	NULL
I	NULL
«	NULL
B	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NFkB	NULL
leads	NULL
to	NULL
its	NULL
dissociation	NULL
from	NULL
I	NULL
«	NULL
xB	NULL
and	NULL
its	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
it	NULL
binds	NULL
to	NULL
sequence-specific	NULL
regulatory	NULL
regions	NULL
of	NULL
several	NULL
genes	NULL
.	NULL

We	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
MM-LDL	NULL
to	NULL
activate	NULL
NFB	NULL
which	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
transcriptional	NULL
regulation	NULL
of	NULL
genes	NULL
by	NULL
MM-LDL	NULL
.	NULL

Methods	NULL
Cell	NULL
preparation	NULL
.	NULL

Rabbit	NULL
aortic	NULL
endothelial	NULL
cells	NULL
(	NULL
RAEC	NULL
)	NULL
at	NULL
passages	NULL
9-17	NULL
and	NULL
human	NULL
aortic	NULL
endothelial	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
or	NULL
human	NULL
aortic	NULL
valve	NULL
cells	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Thomas	NULL
Drake	NULL
,	NULL
UCLA	NULL
School	NULL
of	NULL
Medi-cine	NULL
)	NULL
at	NULL
passages	NULL
4-7	NULL
were	NULL
used	NULL
.	NULL

For	NULL
these	NULL
studies	NULL
,	NULL
human	NULL
monocytes	NULL
were	NULL
obtained	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
Recalde	NULL
method	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
)	NULL
.	NULL

The	NULL
human	NULL
neutrophil	NULL
cell	NULL
line	NULL
HL60	NULL
(	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
source	NULL
of	NULL
neutrophil-like	NULL
cells	NULL
.	NULL

Leukocyte	NULL
adhesion	NULL
assay	NULL
.	NULL

For	NULL
adhesion	NULL
studies	NULL
,	NULL
endothelial	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
gelatin-coated	NULL
48-well	NULL
dishes	NULL
,	NULL
in	NULL
DME	NULL
containing	NULL
15	NULL
%	NULL
calf	NULL
serum	NULL
(	NULL
CS	NULL
)	NULL
,	NULL
5	NULL
ug/ml	NULL
endothelial	NULL
cell	NULL
growth	NULL
supplement	NULL
(	NULL
ECGS	NULL
)	NULL
,	NULL
and	NULL
8	NULL
ug/ml	NULL
heparin	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

When	NULL
confluent	NULL
monolayers	NULL
were	NULL
formed	NULL
,	NULL
medium	NULL
was	NULL
changed	NULL
to	NULL
DME	NULL
containing	NULL
10	NULL
%	NULL
CS	NULL
without	NULL
ECGS	NULL
and	NULL
heparin	NULL
24	NULL
h	NULL
before	NULL
the	NULL
experi-ment	NULL
.	NULL

This	NULL
medium	NULL
was	NULL
then	NULL
removed	NULL
and	NULL
agonists	NULL
added	NULL
to	NULL
cells	NULL
in	NULL
DME	NULL
with	NULL
5	NULL
%	NULL
CS	NULL
.	NULL

The	NULL
gradual	NULL
lowering	NULL
of	NULL
the	NULL
serum	NULL
concentration	NULL
minimized	NULL
the	NULL
basal	NULL
levels	NULL
of	NULL
leukocyte	NULL
binding	NULL
to	NULL
the	NULL
endothelial	NULL
monolayer	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
LPS	NULL
in	NULL
medium	NULL
containing	NULL
each	NULL
agonist	NULL
was	NULL
<	NULL
50	NULL
pg/ml	NULL
as	NULL
determined	NULL
by	NULL
chromogenic	NULL
assay	NULL
.	NULL

This	NULL
level	NULL
of	NULL
LPS	NULL
when	NULL
present	NULL
in	NULL
LDL	NULL
is	NULL
~	NULL
50-fold	NULL
less	NULL
than	NULL
required	NULL
to	NULL
induce	NULL
monocyte	NULL
binding	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

After	NULL
4	NULL
h	NULL
of	NULL
incubation	NULL
with	NULL
agonists	NULL
at	NULL
37°C	NULL
,	NULL
the	NULL
endothelial	NULL
monolayer	NULL
was	NULL
rinsed	NULL
twice	NULL
with	NULL
DME	NULL
containing	NULL
5	NULL
%	NULL
CS	NULL
and	NULL
leukocytes	NULL
were	NULL
added	NULL
at	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
.	NULL

After	NULL
20	NULL
min	NULL
incubation	NULL
at	NULL
37°C	NULL
,	NULL
the	NULL
unbound	NULL
leukocytes	NULL
were	NULL
removed	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
glutaraldehyde	NULL
in	NULL
PBS	NULL
.	NULL

The	NULL
number	NULL
of	NULL
bound	NULL
leukocytes	NULL
was	NULL
determined	NULL
by	NULL
counting	NULL
a	NULL
minimum	NULL
of	NULL
six	NULL
fields	NULL
per	NULL
well	NULL
using	NULL
light	NULL
microscopy	NULL
.	NULL

Lipoprotein	NULL
preparation	NULL
.	NULL

LDL	NULL
was	NULL
isolated	NULL
by	NULL
density	NULL
gradient	NULL
centrifugation	NULL
of	NULL
serum	NULL
and	NULL
stored	NULL
in	NULL
phosphate-buffered	NULL
0.15	NULL
M	NULL
NaCl	NULL
containing	NULL
0.01	NULL
%	NULL
EDTA	NULL
.	NULL

MM-LDL	NULL
was	NULL
made	NULL
using	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
method	NULL
by	NULL
Sparrow	NULL
et	NULL
al	NULL
.	NULL

(	NULL
34	NULL
)	NULL
using	NULL
soybean	NULL
lipoxygenase	NULL
(	NULL
SLO	NULL
)	NULL
and	NULL
phospholipase	NULL
A	NULL
,	NULL
(	NULL
PLA	NULL
;	NULL
,	NULL
)	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

SLO	NULL
and	NULL
PLA	NULL
,	NULL
were	NULL
separately	NULL
bound	NULL
to	NULL
CNBr-activated	NULL
sepharose	NULL
beads	NULL
(	NULL
Pharmacia	NULL
Inc.	NULL
,	NULL
Piscata-way	NULL
,	NULL
NJ	NULL
)	NULL
in	NULL
coupling	NULL
buffer	NULL
(	NULL
0.1	NULL
M	NULL
NaHCO	NULL
;	NULL
,	NULL
0.5	NULL
M	NULL
NaCl	NULL
,	NULL
pH	NULL
8.3	NULL
)	NULL
.	NULL

Approximately	NULL
1,700	NULL
U	NULL
of	NULL
SLO	NULL
and	NULL
4	NULL
U	NULL
of	NULL
PLA	NULL
,	NULL
were	NULL
bound	NULL
per	NULL
mg	NULL
of	NULL
472	NULL
_	NULL
Parhami	NULL
,	NULL
Fang	NULL
,	NULL
Fogelman	NULL
,	NULL
Andalibi	NULL
,	NULL
Territo	NULL
,	NULL
and	NULL
Berliner	NULL
beads	NULL
.	NULL

LDL	NULL
was	NULL
used	NULL
after	NULL
dialysis	NULL
against	NULL
PBS	NULL
to	NULL
remove	NULL
the	NULL
EDTA	NULL
.	NULL

0.5	NULL
mg	NULL
of	NULL
LDL	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
PBS	NULL
was	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
24	NULL
h	NULL
with	NULL
20	NULL
U	NULL
of	NULL
PLA	NULL
;	NULL
,	NULL
,	NULL
5,000	NULL
U	NULL
of	NULL
SLO	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
CaCl	NULL
;	NULL
in	NULL
12	NULL
x	NULL
75	NULL
mm	NULL
sterile	NULL
polypropylene	NULL
snap	NULL
cap	NULL
tubes	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
an	NULL
additional	NULL
5,000	NULL
U	NULL
of	NULL
SLO	NULL
was	NULL
added	NULL
and	NULL
tubes	NULL
were	NULL
incubated	NULL
another	NULL
24	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
enzymes	NULL
were	NULL
removed	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
butylated	NULL
hydroxy-toluene	NULL
and	NULL
EDTA	NULL
were	NULL
added	NULL
at	NULL
100	NULL
«	NULL
M	NULL
and	NULL
0.3	NULL
mM	NULL
,	NULL
respectively	NULL
.	NULL

Preparations	NULL
of	NULL
MM-LDL	NULL
used	NULL
for	NULL
these	NULL
studies	NULL
contained	NULL
between	NULL
20	NULL
and	NULL
50	NULL
pg	NULL
LPS/ml	NULL
of	NULL
medium	NULL
.	NULL

This	NULL
enzymatic	NULL
modification	NULL
of	NULL
LDL	NULL
has	NULL
generated	NULL
biologically	NULL
active	NULL
MM-LDL	NULL
that	NULL
has	NULL
been	NULL
stable	NULL
for	NULL
several	NULL
months	NULL
at	NULL
4°C	NULL
.	NULL

Iron-oxidized	NULL
LDL	NULL
(	NULL
12	NULL
,	NULL
35	NULL
)	NULL
,	NULL
copper-oxidized	NULL
LDL	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
,	NULL
and	NULL
malondialdehyde	NULL
(	NULL
MDA	NULL
)	NULL
-LDL	NULL
(	NULL
38	NULL
)	NULL
were	NULL
made	NULL
according	NULL
to	NULL
the	NULL
previously	NULL
published	NULL
methods	NULL
.	NULL

LDL	NULL
was	NULL
minimally	NULL
oxidized	NULL
by	NULL
iron	NULL
and	NULL
highly	NULL
oxidized	NULL
by	NULL
copper	NULL
,	NULL
giving	NULL
2	NULL
and	NULL
10	NULL
nmol	NULL
of	NULL
thiobarbituric	NULL
acid-reactive	NULL
substances	NULL
per	NULL
mg	NULL
of	NULL
cholesterol	NULL
after	NULL
dialysis	NULL
,	NULL
respectively	NULL
.	NULL

Northern	NULL
analysis	NULL
.	NULL

Endothelial	NULL
cells	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
4	NULL
h	NULL
with	NULL
or	NULL
without	NULL
agonist	NULL
in	NULL
DME	NULL
containing	NULL
5	NULL
%	NULL
CS	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
cells	NULL
using	NULL
guanidine	NULL
thiocyanate/phenol	NULL
method	NULL
(	NULL
39	NULL
)	NULL
.	NULL

10	NULL
ug	NULL
of	NULL
RNA	NULL
was	NULL
denatured	NULL
at	NULL
65°C	NULL
for	NULL
10	NULL
min	NULL
in	NULL
2.2	NULL
M	NULL
formaldehyde	NULL
and	NULL
50	NULL
%	NULL
deionized	NULL
formamide	NULL
and	NULL
was	NULL
electrophoresed	NULL
through	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
containing	NULL
2.2	NULL
M	NULL
formaldehyde	NULL
.	NULL

RNA	NULL
was	NULL
transblotted	NULL
to	NULL
a	NULL
nylon	NULL
membrane	NULL
(	NULL
Hybond-N	NULL
;	NULL
Amersham	NULL
Corp.	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
and	NULL
cross-linked	NULL
by	NULL
ultraviolet	NULL
light	NULL
.	NULL

The	NULL
blot	NULL
was	NULL
prehy-bridized	NULL
at	NULL
65°C	NULL
for	NULL
2	NULL
h	NULL
in	NULL
0.15	NULL
M	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
,	NULL
0.25	NULL
M	NULL
NaH	NULL
,	NULL
PO	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
7	NULL
%	NULL
SDS	NULL
,	NULL
and	NULL
1	NULL
%	NULL
BSA	NULL
,	NULL
pH	NULL
7.0	NULL
,	NULL
and	NULL
hybridized	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
at	NULL
65°C	NULL
overnight	NULL
with	NULL
P-labeled	NULL
DNA	NULL
probes	NULL
for	NULL
alpha	NULL
tubulin	NULL
,	NULL
MCP-1	NULL
(	NULL
9	NULL
)	NULL
,	NULL
M-CSF	NULL
(	NULL
10	NULL
)	NULL
,	NULL
or	NULL
endothelial	NULL
leukocyte	NULL
adhesion	NULL
molecule	NULL
(	NULL
ELAM	NULL
)	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Brian	NULL
Seed	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

After	NULL
hybridization	NULL
,	NULL
the	NULL
blot	NULL
was	NULL
washed	NULL
twice	NULL
at	NULL
room	NULL
temperature	NULL
in	NULL
2	NULL
%	NULL
SSC/0.1	NULL
%	NULL
SDS	NULL
,	NULL
and	NULL
twice	NULL
at	NULL
65°C	NULL
in	NULL
0.5	NULL
%	NULL
SSC/0.1	NULL
%	NULL
SDS	NULL
,	NULL
for	NULL
20	NULL
min	NULL
each	NULL
,	NULL
and	NULL
exposed	NULL
to	NULL
x-ray	NULL
film	NULL
at	NULL
-70°C	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
induction	NULL
was	NULL
determined	NULL
by	NULL
densitometric	NULL
scanning	NULL
.	NULL

cAMP	NULL
measurement	NULL
.	NULL

For	NULL
measuring	NULL
cAMP	NULL
levels	NULL
,	NULL
RAEC	NULL
were	NULL
cultured	NULL
in	NULL
60-mm	NULL
dishes	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
pretreated	NULL
for	NULL
10	NULL
min	NULL
with	NULL
0.5	NULL
mM	NULL
3-isobutyl-l-methylxanthine	NULL
(	NULL
IBMX	NULL
,	NULL
Calbiochem	NULL
Corp.	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
cAMP	NULL
phosphodiesterase	NULL
,	NULL
in	NULL
DME	NULL
containing	NULL
5	NULL
%	NULL
CS	NULL
.	NULL

Agonists	NULL
were	NULL
then	NULL
added	NULL
and	NULL
cells	NULL
collected	NULL
at	NULL
several	NULL
time	NULL
points	NULL
after	NULL
being	NULL
rinsed	NULL
twice	NULL
with	NULL
PBS	NULL
containing	NULL
4	NULL
mM	NULL
EDTA	NULL
(	NULL
also	NULL
an	NULL
inhibitor	NULL
of	NULL
cAMP	NULL
phosphodiesterase	NULL
)	NULL
and	NULL
scraped	NULL
into	NULL
the	NULL
same	NULL
buffer	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
after	NULL
centrifugation	NULL
was	NULL
resuspended	NULL
in	NULL
100	NULL
l	NULL
of	NULL
boiling	NULL
water	NULL
containing	NULL
4	NULL
mM	NULL
EDTA	NULL
.	NULL

The	NULL
suspension	NULL
was	NULL
sonicated	NULL
,	NULL
heated	NULL
3	NULL
min	NULL
in	NULL
a	NULL
boiling	NULL
water	NULL
bath	NULL
,	NULL
and	NULL
microcentrifuged	NULL
for	NULL
2	NULL
min	NULL
at	NULL
high	NULL
speed	NULL
to	NULL
spin	NULL
out	NULL
the	NULL
coagulated	NULL
proteins	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
cAMP	NULL
levels	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

RAEC	NULL
were	NULL
cultured	NULL
in	NULL
100-mm	NULL
dishes	NULL
.	NULL

Approximately	NULL
10°	NULL
cells	NULL
were	NULL
used	NULL
per	NULL
condition	NULL
.	NULL

After	NULL
treatment	NULL
with	NULL
agonist	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
rinsed	NULL
twice	NULL
with	NULL
ice-cold	NULL
and	NULL
scraped	NULL
into	NULL
ice-cold	NULL
PBS	NULL
.	NULL

The	NULL
pellet	NULL
was	NULL
frozen	NULL
in	NULL
a	NULL
dry	NULL
ice/eth-anol	NULL
bath	NULL
and	NULL
stored	NULL
at	NULL
-70°C	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Osborn	NULL
et	NULL
al	NULL
.	NULL

(	NULL
40	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
was	NULL
performed	NULL
using	NULL
6	NULL
%	NULL
non-denaturing	NULL
polyacrylamide	NULL
gel	NULL
according	NULL
to	NULL
the	NULL
protocol	NULL
provided	NULL
in	NULL
NFkB	NULL
DNA	NULL
binding	NULL
protein	NULL
detection	NULL
system	NULL
from	NULL
Gibco-Bethesda	NULL
Research	NULL
Laboratories	NULL
(	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
double-stranded	NULL
oligonucleotide	NULL
supplied	NULL
is	NULL
a	NULL
40	NULL
mer	NULL
containing	NULL
a	NULL
tandem	NULL
repeat	NULL
of	NULL
the	NULL
consensus	NULL
sequence	NULL
for	NULL
NFxB	NULL
DNA	NULL
binding	NULL
site	NULL
,	NULL
-GGGGACTTTCC-	NULL
.	NULL

To	NULL
facilitate	NULL
our	NULL
studies	NULL
,	NULL
a	NULL
new	NULL
method	NULL
of	NULL
producing	NULL
MM-LDL	NULL
has	NULL
been	NULL
developed	NULL
that	NULL
is	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
procedure	NULL
of	NULL
Sparrow	NULL
et	NULL
al	NULL
.	NULL

(	NULL
34	NULL
)	NULL
involving	NULL
treatment	NULL
of	NULL
LDL	NULL
with	NULL
SLO	NULL
and	NULL
PLA	NULL
;	NULL
.	NULL

This	NULL
method	NULL
has	NULL
several	NULL
advantages	NULL
compared	NULL
with	NULL
our	NULL
previous	NULL
method	NULL
of	NULL
long-term	NULL
storage	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
new	NULL
method	NULL
takes	NULL
several	NULL
days	NULL
as	NULL
compared	NULL
with	NULL
6-12	NULL
mo	NULL
,	NULL
and	NULL
LDL	NULL
from	NULL
20	NULL
consecutive	NULL
donors	NULL
treated	NULL
in	NULL
this	NULL
manner	NULL
yielded	NULL
biologically	NULL
active	NULL
MM-LDL	NULL
.	NULL

This	NULL
enzymatic	NULL
modification	NULL
produced	NULL
a	NULL
low	NULL
level	NULL
of	NULL
oxidation	NULL
of	NULL
LDL	NULL
resulting	NULL
in	NULL
only	NULL
a	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
in	NULL
conjugated	NULL
dienes	NULL
,	NULL
an	NULL
increase	NULL
similar	NULL
to	NULL
that	NULL
seen	NULL
after	NULL
cold	NULL
storage	NULL
.	NULL

Like	NULL
LDL	NULL
that	NULL
was	NULL
minimally	NULL
oxidized	NULL
by	NULL
storage	NULL
,	NULL
LDL	NULL
oxidized	NULL
by	NULL
lipoxygenase	NULL
and	NULL
PLA	NULL
,	NULL
caused	NULL
an	NULL
induction	NULL
of	NULL
monocyte	NULL
but	NULL
not	NULL
neutrophil	NULL
binding	NULL
to	NULL
RAEC	NULL
treated	NULL
for	NULL
4	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
such	NULL
MM-LDL	NULL
preparations	NULL
induced	NULL
the	NULL
synthesis	NULL
of	NULL
mRNA	NULL
for	NULL
MCP-1	NULL
and	NULL
M-CSF	NULL
,	NULL
whereas	NULL
native	NULL
LDL	NULL
did	NULL
not	NULL
cause	NULL
such	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
4	NULL
)	NULL
.	NULL

Characterization	NULL
of	NULL
second	NULL
messengers	NULL
.	NULL

We	NULL
initially	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
PKC	NULL
in	NULL
mediating	NULL
the	NULL
effects	NULL
of	NULL
MM-LDL	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
chronic	NULL
incubation	NULL
of	NULL
cells	NULL
with	NULL
phorbol	NULL
esters	NULL
depletes	NULL
the	NULL
cellular	NULL
content	NULL
of	NULL
PKCa	NULL
and	NULL
-	NULL
$	NULL
,	NULL
which	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
the	NULL
most	NULL
prevalent	NULL
forms	NULL
in	NULL
endothelial	NULL
cells	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
RAEC	NULL
for	NULL
4	NULL
h	NULL
with	NULL
10-40	NULL
nM	NULL
PMA	NULL
caused	NULL
a	NULL
strong	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
that	NULL
was	NULL
significantly	NULL
down-regulated	NULL
by	NULL
a	NULL
48-h	NULL
pretreatment	NULL
with	NULL
10	NULL
nm	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
4	NULL
)	NULL
.	NULL

This	NULL
pretreatment	NULL
did	NULL
not	NULL
down-regulate	NULL
the	NULL
binding	NULL
induced	NULL
by	NULL
MM-LDL	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
4	NULL
)	NULL
but	NULL
markedly	NULL
down-regulated	NULL
PKC	NULL
activity	NULL
in	NULL
the	NULL
pretreated	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
PMA	NULL
pretreatment	NULL
also	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
induction	NULL
of	NULL
mRNA	NULL
levels	NULL
for	NULL
M-CSF	NULL
by	NULL
MM-LDL	NULL
whereas	NULL
induction	NULL
by	NULL
PMA	NULL
was	NULL
inhibited	NULL
significantly	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
MM-LDL-induced	NULL
increase	NULL
in	NULL
M-CSF	NULL
mRNA	NULL
was	NULL
450	NULL
7	NULL
400	NULL
7	NULL
MONO	NULL
F	NULL
]	NULL
HL6O	NULL
350	NULL
300	NULL
7	NULL
S	NULL
/A	NULL
P	NULL
250	NULL
7	NULL
t	NULL
200	NULL
7	NULL
Sop	NULL
CELLS/HPF	NULL
sss	NULL
1507	NULL
100	NULL
7	NULL
Ss	NULL
S	NULL
sss	NULL
P	NULL
Ss	NULL
sss	NULL
St	NULL
C	NULL
L	NULL
NL	NULL
M	NULL
CT	NULL
PT	NULL
c	NULL
A	NULL
Figure	NULL
1	NULL
.	NULL

Induction	NULL
of	NULL
leukocyte	NULL
binding	NULL
to	NULL
endothelial	NULL
cells	NULL
.	NULL

RAEC	NULL
were	NULL
incubated	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
no	NULL
additives	NULL
(	NULL
C	NULL
'	NULL
)	NULL
,	NULL
LPS	NULL
3	NULL
ng/ml	NULL
(	NULL
L	NULL
)	NULL
as	NULL
the	NULL
positive	NULL
control	NULL
,	NULL
native	NULL
LDL	NULL
125	NULL
ug/ml	NULL
(	NULL
NL	NULL
)	NULL
,	NULL
MM-LDL	NULL
125	NULL
ug/ml	NULL
(	NULL
M	NULL
)	NULL
,	NULL
cholera	NULL
toxin	NULL
400	NULL
ng/ml	NULL
(	NULL
CT	NULL
)	NULL
,	NULL
pertussis	NULL
toxin	NULL
30	NULL
ng/ml	NULL
(	NULL
PT	NULL
)	NULL
,	NULL
dbcAMP	NULL
1	NULL
mM	NULL
(	NULL
cA	NULL
)	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
leukocyte	NULL
adhesion	NULL
assay	NULL
was	NULL
performed	NULL
using	NULL
human	NULL
monocytes	NULL
or	NULL
a	NULL
neutrophil-like	NULL
cell	NULL
line	NULL
(	NULL
HL60	NULL
)	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
out	NULL
of	NULL
three	NULL
experiments	NULL
and	NULL
the	NULL
values	NULL
from	NULL
a	NULL
representative	NULL
experiment	NULL
are	NULL
reported	NULL
as	NULL
the	NULL
mean	NULL
number	NULL
of	NULL
monocytes	NULL
bound	NULL
per	NULL
high	NULL
power	NULL
field	NULL
(	NULL
Xx100	NULL
)	NULL
+SEM	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
(	NULL
p	NULL
<	NULL
0.001	NULL
for	NULL
C	NULL
vs.	NULL
M	NULL
,	NULL
C	NULL
vs.	NULL
CT	NULL
,	NULL
C	NULL
vs.	NULL
PT	NULL
,	NULL
and	NULL
C	NULL
vs.	NULL
cA	NULL
in	NULL
the	NULL
monocyte	NULL
binding	NULL
assay	NULL
)	NULL
.	NULL

»	NULL
=	NULL
number	NULL
of	NULL
fields	NULL
counted	NULL
for	NULL
each	NULL
condition	NULL
in	NULL
the	NULL
experiments	NULL
.	NULL

1	NULL
||	NULL
«	NULL
4	NULL
M-CSF	NULL
-a-	NULL
TUBULIN	NULL
-a-	NULL
MCP-1	NULL
Figure	NULL
2	NULL
.	NULL

(	NULL
A	NULL
,	NULL
B	NULL
,	NULL
C	NULL
)	NULL
Induction	NULL
of	NULL
MCP-1	NULL
and	NULL
M-CSF	NULL
mRNA	NULL
.	NULL

RAEC	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
4	NULL
h	NULL
with	NULL
no	NULL
additives	NULL
(	NULL
C	NULL
)	NULL
,	NULL
LPS	NULL
3	NULL
ng/ml	NULL
(	NULL
L	NULL
)	NULL
,	NULL
MM-LDL	NULL
125	NULL
ug/ml	NULL
(	NULL
M	NULL
)	NULL
,	NULL
native	NULL
LDL	NULL
125	NULL
ug/ml	NULL
(	NULL
NL	NULL
)	NULL
,	NULL
cholera	NULL
toxin	NULL
400	NULL
ng/ml	NULL
(	NULL
CT	NULL
)	NULL
,	NULL
or	NULL
dbcAMP	NULL
1	NULL
mM	NULL
(	NULL
c4	NULL
)	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
in	NULL
DME	NULL
containing	NULL
5	NULL
%	NULL
calf	NULL
serum	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
probing	NULL
for	NULL
MCP-1	NULL
,	NULL
M-CSF	NULL
,	NULL
and	NULL
alpha	NULL
tubulin	NULL
.	NULL

All	NULL
CT	NULL
M+CT	NULL
§	NULL
)	NULL
«	NULL
<	NULL
-	NULL
m-csF	NULL
Tubuli	NULL
mag	NULL
t	NULL
Northern	NULL
analyses	NULL
were	NULL
zzz	NULL
...	NULL
MCP	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
previously	NULL
reported	NULL
methods	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

lower	NULL
than	NULL
that	NULL
induced	NULL
by	NULL
PMA	NULL
,	NULL
similar	NULL
findings	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
out	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
PKC	NULL
is	NULL
not	NULL
the	NULL
second	NULL
messenger	NULL
involved	NULL
in	NULL
mediating	NULL
the	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
and	NULL
increase	NULL
of	NULL
M-CSF	NULL
mRNA	NULL
by	NULL
MM-LDL	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
cAMP	NULL
in	NULL
the	NULL
MM-LDL-induced	NULL
cellular	NULL
responses	NULL
.	NULL

Incubation	NULL
of	NULL
RAEC	NULL
with	NULL
MM-LDL	NULL
resulted	NULL
in	NULL
a	NULL
40	NULL
and	NULL
173	NULL
%	NULL
elevation	NULL
of	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
after	NULL
10	NULL
min	NULL
and	NULL
2	NULL
h	NULL
of	NULL
treatment	NULL
,	NULL
respectively	NULL
.	NULL

CT	NULL
and	NULL
PT	NULL
both	NULL
induced	NULL
similar	NULL
cellular	NULL
responses	NULL
as	NULL
MM-LDL	NULL
.	NULL

Incubation	NULL
of	NULL
RAEC	NULL
with	NULL
CT	NULL
for	NULL
2	NULL
h	NULL
and	NULL
with	NULL
PT	NULL
for	NULL
1	NULL
h	NULL
increased	NULL
cAMP	NULL
levels	NULL
100	NULL
and	NULL
200	NULL
%	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Both	NULL
CT	NULL
and	NULL
PT	NULL
treatment	NULL
of	NULL
RAEC	NULL
for	NULL
4	NULL
h	NULL
caused	NULL
a	NULL
concentration-de-pendent	NULL
induction	NULL
of	NULL
monocyte	NULL
but	NULL
not	NULL
HL60	NULL
binding	NULL
,	NULL
with	NULL
maximum	NULL
responses	NULL
at	NULL
400	NULL
ng/ml	NULL
of	NULL
CT	NULL
and	NULL
30	NULL
ng/ml	NULL
of	NULL
PT	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Both	NULL
monocyte	NULL
and	NULL
HL60	NULL
binding	NULL
were	NULL
induced	NULL
by	NULL
LPS	NULL
10-	NULL
and	NULL
20-fold	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
additive	NULL
effect	NULL
of	NULL
CT	NULL
+	NULL
MM-LDL	NULL
(	NULL
p	NULL
=	NULL
0.4579	NULL
,	NULL
n	NULL
=	NULL
6	NULL
)	NULL
or	NULL
PT	NULL
+	NULL
MM-LDL	NULL
(	NULL
p	NULL
=	NULL
0.3307	NULL
,	NULL
n	NULL
=	NULL
6	NULL
)	NULL
compared	NULL
with	NULL
each	NULL
toxin	NULL
alone	NULL
,	NULL
even	NULL
though	NULL
maximal	NULL
monocyte	NULL
binding	NULL
had	NULL
not	NULL
been	NULL
obtained	NULL
(	NULL
as	NULL
seen	NULL
in	NULL
LPS-treated	NULL
cells	NULL
)	NULL
.	NULL

This	NULL
lack	NULL
of	NULL
additivity	NULL
suggests	NULL
that	NULL
MM-LDL	NULL
,	NULL
CT	NULL
,	NULL
and	NULL
PT	NULL
may	NULL
act	NULL
via	NULL
similar	NULL
signaling	NULL
pathways	NULL
.	NULL

The	NULL
results	NULL
from	NULL
CT	NULL
and	NULL
PT	NULL
studies	NULL
strongly	NULL
suggest	NULL
the	NULL
involvement	NULL
of	NULL
adenylate	NULL
cyclase	NULL
and	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
in	NULL
the	NULL
specific	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
to	NULL
endothelial	NULL
cells	NULL
.	NULL

Further	NULL
evidence	NULL
that	NULL
increased	NULL
cAMP	NULL
levels	NULL
are	NULL
responsi-bie	NULL
for	NULL
the	NULL
effects	NULL
of	NULL
MM-LDL	NULL
on	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
was	NULL
suggested	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
pretreatment	NULL
of	NULL
cells	NULL
with	NULL
0.2	NULL
mM	NULL
IBMX	NULL
,	NULL
a	NULL
cAMP	NULL
phosphodiesterase	NULL
inhibitor	NULL
,	NULL
for	NULL
10	NULL
min	NULL
before	NULL
MM-LDL	NULL
treatment	NULL
increased	NULL
monocyte	NULL
binding	NULL
to	NULL
MM-LDL-induced	NULL
Inflammatory	NULL
Responses	NULL
Are	NULL
Mediated	NULL
by	NULL
cAMP	NULL
__	NULL
478	NULL
(	NULL
120	NULL
7	NULL
100	NULL
7	NULL
MONOS/HPF	NULL
&	NULL
{	NULL
3	NULL
10	NULL
;	NULL
(	NULL
6	NULL
)	NULL
DENSITOMETRIC	NULL
UNITS	NULL
Po	NULL
PIP	NULL
Pio	NULL
Figure	NULL
3	NULL
.	NULL

MM-LDL	NULL
(	NULL
A	NULL
)	NULL
Induction	NULL
of	NULL
monocyte	NULL
binding	NULL
and	NULL
(	NULL
8	NULL
)	NULL
induction	NULL
of	NULL
mRNA	NULL
for	NULL
M-CSF	NULL
are	NULL
not	NULL
PKC	NULL
mediated	NULL
.	NULL

(	NULL
4	NULL
)	NULL
RAEC	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
4	NULL
h	NULL
with	NULL
no	NULL
additives	NULL
(	NULL
C	NULL
)	NULL
,	NULL
LPS	NULL
3	NULL
ng/ml	NULL
(	NULL
L	NULL
)	NULL
,	NULL
MM-LDL	NULL
125	NULL
ug/ml	NULL
(	NULL
Mf	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
40	NULL
nM	NULL
(	NULL
P	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
to	NULL
deplete	NULL
the	NULL
cellular	NULL
content	NULL
of	NULL
PKC	NULL
,	NULL
cells	NULL
were	NULL
first	NULL
pretreated	NULL
with	NULL
10	NULL
nM	NULL
PMA	NULL
in	NULL
DME	NULL
containing	NULL
10	NULL
%	NULL
CS	NULL
for	NULL
48	NULL
h	NULL
,	NULL
indicated	NULL
as	NULL
(	NULL
P/	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
4-h	NULL
treatment	NULL
with	NULL
a	NULL
second	NULL
agonist	NULL
as	NULL
described	NULL
above	NULL
.	NULL

P/O	NULL
indicates	NULL
48	NULL
h	NULL
pretreatment	NULL
with	NULL
10	NULL
nM	NULL
PMA	NULL
with	NULL
no	NULL
further	NULL
treatments	NULL
.	NULL

After	NULL
this	NULL
incubation	NULL
,	NULL
monocyte	NULL
adhesion	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
of	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
out	NULL
of	NULL
three	NULL
experiments	NULL
and	NULL
the	NULL
values	NULL
from	NULL
a	NULL
representative	NULL
experiment	NULL
are	NULL
reported	NULL
as	NULL
the	NULL
mean+SEM	NULL
(	NULL
n	NULL
=	NULL
6	NULL
)	NULL
(	NULL
p	NULL
<	NULL
0.001	NULL
for	NULL
P	NULL
vs.	NULL
P/P	NULL
,	NULL
and	NULL
p	NULL
=	NULL
0.1985	NULL
for	NULL
M	NULL
vs.	NULL
P/M	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
,	NULL
probing	NULL
for	NULL
M-CSF	NULL
and	NULL
alpha	NULL
tubulin	NULL
,	NULL
using	NULL
mRNA	NULL
from	NULL
cells	NULL
treated	NULL
similarly	NULL
to	NULL
those	NULL
in	NULL
4	NULL
.	NULL

The	NULL
signals	NULL
were	NULL
traced	NULL
,	NULL
normalized	NULL
to	NULL
tubulin	NULL
levels	NULL
,	NULL
and	NULL
reported	NULL
in	NULL
densitometric	NULL
units	NULL
.	NULL

RAEC	NULL
as	NULL
compared	NULL
with	NULL
MM-LDL	NULL
alone	NULL
(	NULL
MM-LDL	NULL
=	NULL
76	NULL
,	NULL
IBMX	NULL
+	NULL
MM-LDL	NULL
=	NULL
107	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
,	NULL
n	NULL
»	NULL
=	NULL
12	NULL
)	NULL
.	NULL

Also	NULL
treating	NULL
RAEC	NULL
for	NULL
4	NULL
h	NULL
with	NULL
1	NULL
mM	NULL
dbcAMP	NULL
,	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
taken	NULL
up	NULL
by	NULL
cells	NULL
and	NULL
leads	NULL
to	NULL
increased	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
,	NULL
induced	NULL
monocyte	NULL
binding	NULL
sixfold	NULL
but	NULL
did	NULL
not	NULL
induce	NULL
HL6O	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
treating	NULL
RAEC	NULL
for	NULL
1	NULL
h	NULL
with	NULL
5	NULL
4M	NULL
IP	NULL
caused	NULL
a	NULL
120	NULL
%	NULL
increase	NULL
in	NULL
cAMP	NULL
level	NULL
,	NULL
and	NULL
a	NULL
threefold	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
(	NULL
C	NULL
=	NULL
15	NULL
vs.	NULL
IP	NULL
=	NULL
45	NULL
,	NULL
p	NULL
<	NULL
0.001	NULL
in	NULL
a	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
)	NULL
.	NULL

HL60	NULL
binding	NULL
was	NULL
not	NULL
474	NULL
__	NULL
Parhami	NULL
,	NULL
Fang	NULL
,	NULL
Fogelman	NULL
,	NULL
Andalibi	NULL
,	NULL
Territo	NULL
,	NULL
and	NULL
Berliner	NULL
Table	NULL
I	NULL
.	NULL

The	NULL
Effect	NULL
of	NULL
Lipoproteins	NULL
,	NULL
CT	NULL
,	NULL
PT	NULL
,	NULL
and	NULL
IP	NULL
on	NULL
cAMP	NULL
Levels	NULL
and	NULL
Leukocyte	NULL
Adhesion	NULL
Percent	NULL
Monocyte	NULL
binding	NULL
HL6O	NULL
binding	NULL
Agonist	NULL
change	NULL
induced	NULL
induced	NULL
MM-LDL	NULL
+173	NULL
Yes	NULL
No	NULL
Iron-LDL	NULL
+122	NULL
Yes	NULL
No	NULL
CT	NULL
+100	NULL
Yes	NULL
No	NULL
PT	NULL
+200	NULL
Yes	NULL
No	NULL
IP	NULL
+120	NULL
Yes	NULL
No	NULL
Native	NULL
LDL	NULL
-38	NULL
No	NULL
No	NULL
MDA-LDL	NULL
-20	NULL
No	NULL
No	NULL
Copper-LDL	NULL
-18	NULL
No	NULL
No	NULL
LPC	NULL
-33	NULL
No	NULL
No	NULL
RAEC	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
with	NULL
125	NULL
ug/ml	NULL
MM-LDL	NULL
(	NULL
M	NULL
)	NULL
2	NULL
h	NULL
,	NULL
125	NULL
ug/ml	NULL
!	NULL

iron-oxidized	NULL
LDL	NULL
2	NULL
h	NULL
,	NULL
400	NULL
ng/ml	NULL
CT	NULL
2	NULL
h	NULL
,	NULL
30	NULL
ng/ml	NULL
PT	NULL
1	NULL
h	NULL
,	NULL
5	NULL
aM	NULL
IP	NULL
1	NULL
h	NULL
,	NULL
125	NULL
ug/ml	NULL
native	NULL
LDL	NULL
1	NULL
h	NULL
,	NULL
125	NULL
ug/ml	NULL
MDA-LDL	NULL
2	NULL
h	NULL
,	NULL
125	NULL
ug/ml	NULL
copper-oxidized	NULL
LDL	NULL
2	NULL
h	NULL
,	NULL
or	NULL
100	NULL
aM	NULL
LPC	NULL
2	NULL
h	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0.2	NULL
mM	NULL
IBMX	NULL
.	NULL

cAMP	NULL
levels	NULL
were	NULL
measured	NULL
using	NULL
an	NULL
RIA	NULL
kit	NULL
(	NULL
Amersham	NULL
Corp.	NULL
)	NULL
.	NULL

The	NULL
results	NULL
of	NULL
a	NULL
representative	NULL
experiment	NULL
from	NULL
three	NULL
experiments	NULL
reported	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
duplicate	NULL
determinations	NULL
with	NULL
<	NULL
10	NULL
%	NULL
difference	NULL
between	NULL
the	NULL
duplicates	NULL
are	NULL
shown	NULL
as	NULL
the	NULL
percent	NULL
change	NULL
in	NULL
cAMP	NULL
levels	NULL
compared	NULL
with	NULL
untreated	NULL
cells	NULL
(	NULL
+	NULL
indicates	NULL
an	NULL
increase	NULL
and	NULL
-	NULL
indicates	NULL
a	NULL
decrease	NULL
in	NULL
cAMP	NULL
levels	NULL
)	NULL
.	NULL

Also	NULL
reported	NULL
is	NULL
the	NULL
ability	NULL
of	NULL
each	NULL
agent	NULL
to	NULL
induce	NULL
leukocyte	NULL
binding	NULL
after	NULL
4	NULL
h	NULL
of	NULL
treatment	NULL
.	NULL

induced	NULL
by	NULL
IP	NULL
.	NULL

A	NULL
shorter	NULL
incubation	NULL
period	NULL
with	NULL
IP	NULL
was	NULL
used	NULL
because	NULL
of	NULL
the	NULL
relatively	NULL
transient	NULL
elevation	NULL
of	NULL
cAMP	NULL
by	NULL
this	NULL
agonist	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
believed	NULL
that	NULL
increased	NULL
intracellular	NULL
cAMP	NULL
effects	NULL
are	NULL
mediated	NULL
by	NULL
PK	NULL
A	NULL
(	NULL
22	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
H-8	NULL
,	NULL
a	NULL
PKA	NULL
inhibitor	NULL
,	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
by	NULL
MM-LDL	NULL
.	NULL

Initially	NULL
,	NULL
several	NULL
concentrations	NULL
of	NULL
H-8	NULL
within	NULL
the	NULL
range	NULL
reported	NULL
by	NULL
other	NULL
investigators	NULL
were	NULL
used	NULL
to	NULL
test	NULL
for	NULL
inhibition	NULL
of	NULL
CT	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
.	NULL

H-8	NULL
at	NULL
60	NULL
LM	NULL
inhibited	NULL
induction	NULL
of	NULL
monocyte	NULL
binding	NULL
by	NULL
CT	NULL
by	NULL
50	NULL
%	NULL
.	NULL

RAEC	NULL
pretreated	NULL
with	NULL
H-8	NULL
at	NULL
60	NULL
or	NULL
100	NULL
aM	NULL
for	NULL
1	NULL
h	NULL
demonstrated	NULL
an	NULL
inhibition	NULL
of	NULL
MM-LDL-induced	NULL
monocyte	NULL
binding	NULL
of	NULL
50	NULL
and	NULL
70	NULL
%	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
a	NULL
representative	NULL
experiment	NULL
(	NULL
p	NULL
<	NULL
0.0001	NULL
for	NULL
M	NULL
vs.	NULL
H-8	NULL
at	NULL
both	NULL
concentrations	NULL
;	NULL
r	NULL
=	NULL
10	NULL
)	NULL
.	NULL

The	NULL
increased	NULL
cAMP	NULL
level	NULL
observed	NULL
after	NULL
incubation	NULL
of	NULL
cells	NULL
with	NULL
MM-LDL	NULL
produced	NULL
by	NULL
enzymatic	NULL
modification	NULL
was	NULL
associated	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
this	NULL
lipoprotein	NULL
to	NULL
induce	NULL
monocyte	NULL
but	NULL
not	NULL
HL60	NULL
binding	NULL
.	NULL

Iron-oxidized	NULL
LDL	NULL
,	NULL
which	NULL
has	NULL
similar	NULL
effects	NULL
to	NULL
MM-LDL	NULL
made	NULL
enzymatically	NULL
,	NULL
also	NULL
increased	NULL
cAMP	NULL
levels	NULL
and	NULL
monocyte	NULL
but	NULL
not	NULL
HL60	NULL
binding	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
incubation	NULL
of	NULL
RAEC	NULL
for	NULL
2	NULL
h	NULL
with	NULL
MDA-LDL	NULL
(	NULL
125	NULL
ug/ml	NULL
)	NULL
,	NULL
copper-oxidized	NULL
LDL	NULL
(	NULL
highly	NULL
oxidized	NULL
,	NULL
125	NULL
ug/ml	NULL
)	NULL
,	NULL
or	NULL
lysophosphatidylcholine	NULL
(	NULL
LPC	NULL
,	NULL
100	NULL
aM	NULL
)	NULL
decreased	NULL
cAMP	NULL
levels	NULL
and	NULL
did	NULL
not	NULL
induce	NULL
either	NULL
monocyte	NULL
or	NULL
HL60	NULL
binding	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

The	NULL
possible	NULL
involvement	NULL
of	NULL
cAMP	NULL
elevation	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
mRNA	NULL
for	NULL
MCP-1	NULL
and	NULL
M-CSF	NULL
by	NULL
MM-LDL	NULL
was	NULL
also	NULL
tested	NULL
.	NULL

Like	NULL
MM-LDL	NULL
,	NULL
CT	NULL
treatment	NULL
of	NULL
endothelial	NULL
cells	NULL
increased	NULL
message	NULL
for	NULL
both	NULL
MCP-1	NULL
and	NULL
M-CSF	NULL
twenty-	NULL
and	NULL
four-fold	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
B	NULL
)	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
densitometric	NULL
scanning	NULL
.	NULL

Incubation	NULL
of	NULL
RAEC	NULL
with	NULL
1	NULL
mM	NULL
dbcAMP	NULL
for	NULL
4	NULL
h	NULL
also	NULL
caused	NULL
a	NULL
10-fold	NULL
increase	NULL
in	NULL
MCP-1	NULL
and	NULL
a	NULL
3-fold	NULL
increase	NULL
in	NULL
M-CSF	NULL
mRNA	NULL
levels	NULL
as	NULL
determined	NULL
by	NULL
densitometric	NULL
scanning	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
C	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
M-CSF	NULL
mRNA	NULL
level	NULL
was	NULL
elevated	NULL
approximately	NULL
twofold	NULL
after	NULL
4	NULL
h	NULL
of	NULL
incubation	NULL
with	NULL
IP	NULL
.	NULL

Treatment	NULL
of	NULL
RAEC	NULL
for	NULL
4	NULL
h	NULL
with	NULL
the	NULL
agents	NULL
that	NULL
lowered	NULL
cAMP	NULL
,	NULL
including	NULL
LPC	NULL
(	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
)	NULL
,	NULL
did	NULL
not	NULL
increase	NULL
mRNA	NULL
levels	NULL
for	NULL
M-CSF	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

MM-LDL	NULL
activates	NULL
NFxB	NULL
.	NULL

Previous	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
NF	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
cytosolic	NULL
extracts	NULL
is	NULL
at	NULL
least	NULL
partly	NULL
mediated	NULL
by	NULL
phosphorylation	NULL
of	NULL
the	NULL
NFxB/IxB	NULL
complex	NULL
by	NULL
PK	NULL
A	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
MM-LDL	NULL
to	NULL
activate	NULL
NF	NULL
«	NULL
B	NULL
was	NULL
assessed	NULL
by	NULL
incubating	NULL
RAEC	NULL
with	NULL
MM-LDL	NULL
for	NULL
2	NULL
h	NULL
and	NULL
testing	NULL
for	NULL
enhanced	NULL
NF	NULL
«	NULL
B	NULL
binding	NULL
to	NULL
a	NULL
labeled	NULL
sequence-specific	NULL
oligonucleotide	NULL
in	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
A4	NULL
there	NULL
was	NULL
significant	NULL
activation	NULL
of	NULL
NFxB	NULL
by	NULL
LPS	NULL
and	NULL
MM-LDL	NULL
,	NULL
but	NULL
not	NULL
by	NULL
native	NULL
LDL	NULL
.	NULL

This	NULL
experiment	NULL
was	NULL
performed	NULL
with	NULL
four	NULL
different	NULL
MM-LDL	NULL
preparations	NULL
,	NULL
all	NULL
of	NULL
which	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

CT	NULL
treatment	NULL
of	NULL
RAEC	NULL
for	NULL
2	NULL
h	NULL
also	NULL
caused	NULL
activation	NULL
of	NULL
NFxB	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
B	NULL
)	NULL
.	NULL

Why	NULL
neutrophil	NULL
binding	NULL
is	NULL
not	NULL
increased	NULL
by	NULL
MM-LDL	NULL
.	NULL

ELAM	NULL
is	NULL
the	NULL
major	NULL
neutrophil-binding	NULL
molecule	NULL
on	NULL
endothelial	NULL
cell	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
MM-LDL	NULL
did	NULL
not	NULL
increase	NULL
surface	NULL
expression	NULL
of	NULL
ELAM	NULL
whereas	NULL
LPS	NULL
increased	NULL
expression	NULL
fourfold	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
4	NULL
)	NULL
.	NULL

MM-LDL	NULL
in	NULL
contrast	NULL
to	NULL
LPS	NULL
caused	NULL
only	NULL
a	NULL
minimal	NULL
increase	NULL
in	NULL
ELAM	NULL
mRNA	NULL
levels	NULL
,	NULL
whereas	NULL
both	NULL
agents	NULL
caused	NULL
a	NULL
major	NULL
elevation	NULL
of	NULL
MCP-1	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
induction	NULL
of	NULL
neutrophil	NULL
binding	NULL
was	NULL
actually	NULL
inhibited	NULL
by	NULL
agents	NULL
that	NULL
elevate	NULL
cAMP	NULL
levels	NULL
,	NULL
A	NULL
«	NULL
@	NULL
-NFxB	NULL
C	NULL
M	NULL
M*	NULL
NL	NULL
NL	NULL
'	NULL
L	NULL
L*	NULL
B	NULL
FB	NULL
L	NULL
CT	NULL
C	NULL
M	NULL
Figure	NULL
4	NULL
.	NULL

NFxB	NULL
activation	NULL
by	NULL
MM-LDL	NULL
or	NULL
CT.	NULL
(	NULL
4	NULL
)	NULL
RAEC	NULL
were	NULL
treated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
no	NULL
additives	NULL
(	NULL
C	NULL
)	NULL
,	NULL
MM-LDL	NULL
125	NULL
ug/ml	NULL
(	NULL
M	NULL
)	NULL
,	NULL
native	NULL
LDL	NULL
125	NULL
ug/ml	NULL
(	NULL
NL	NULL
)	NULL
,	NULL
or	NULL
LPS	NULL
3	NULL
ng/ml	NULL
(	NULL
L	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
was	NULL
performed	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
these	NULL
cells	NULL
following	NULL
incubation	NULL
with	NULL
P-labeled	NULL
sequence-specific	NULL
oligonucleotide	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
(	NULL
*	NULL
)	NULL
of	NULL
unlabeled	NULL
competitor	NULL
oligonucleotide	NULL
.	NULL

(	NULL
B	NULL
)	NULL
RAEC	NULL
were	NULL
treated	NULL
with	NULL
LPS	NULL
(	NULL
L	NULL
)	NULL
,	NULL
cholera	NULL
toxin	NULL
(	NULL
CT	NULL
)	NULL
,	NULL
no	NULL
additives	NULL
(	NULL
C	NULL
)	NULL
,	NULL
or	NULL
MM-LDL	NULL
(	NULL
M	NULL
)	NULL
under	NULL
similar	NULL
conditions	NULL
as	NULL
in	NULL
4	NULL
.	NULL

All	NULL
experiments	NULL
on	NULL
activation	NULL
of	NULL
NF	NULL
«	NULL
B	NULL
were	NULL
performed	NULL
on	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
tested	NULL
for	NULL
responsiveness	NULL
to	NULL
the	NULL
agents	NULL
used	NULL
in	NULL
adhesion	NULL
and	NULL
mRNA	NULL
studies	NULL
.	NULL

A	NULL
C	NULL
M	NULL
L	NULL
Clg	NULL
8	NULL
+3	NULL
8.5+0.6	NULL
10.3	NULL
+1	NULL
Anti-ELAM	NULL
8.3	NULL
+1	NULL
8.4	NULL
+	NULL
2.1	NULL
27.5+3	NULL
B	NULL
HAVC	NULL
HAEC	NULL
w	NULL
w	NULL
<	NULL
gg__	NULL
EL	NULL
AM	NULL
-a-	NULL
TUBULIN	NULL
|	NULL
ms	NULL
.	NULL

-a-	NULL
MCP-1	NULL
Figure	NULL
5	NULL
.	NULL

Induction	NULL
of	NULL
ELAM	NULL
(	NULL
4	NULL
)	NULL
protein	NULL
and	NULL
(	NULL
B	NULL
)	NULL
mRNA	NULL
.	NULL

(	NULL
4	NULL
)	NULL
ELISA	NULL
assay	NULL
of	NULL
ELAM	NULL
on	NULL
cell	NULL
surface	NULL
was	NULL
performed	NULL
.	NULL

Human	NULL
aortic	NULL
endothelial	NULL
cells	NULL
,	NULL
cultured	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
9	NULL
)	NULL
,	NULL
were	NULL
incubated	NULL
with	NULL
no	NULL
additives	NULL
(	NULL
C	NULL
)	NULL
,	NULL
MM-LDL	NULL
100	NULL
ug/ml	NULL
(	NULL
44	NULL
)	NULL
,	NULL
or	NULL
LPS	NULL
1	NULL
ng/ml	NULL
(	NULL
L	NULL
)	NULL
for	NULL
4	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
exposed	NULL
to	NULL
control	NULL
IgG	NULL
(	NULL
Cig	NULL
,	NULL
anti-CD3	NULL
)	NULL
or	NULL
anti-ELAM	NULL
antibody	NULL
P6E2	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Cytel	NULL
Corporation	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
1	NULL
h	NULL
,	NULL
followed	NULL
by	NULL
peroxidase-labeled	NULL
goat	NULL
anti-mouse	NULL
secondary	NULL
antibody	NULL
for	NULL
2	NULL
h.	NULL
P6E2	NULL
,	NULL
an	NULL
Ig3	NULL
,	NULL
cross-reacted	NULL
with	NULL
the	NULL
ELAM-1	NULL
protein	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
H18/7	NULL
(	NULL
57	NULL
)	NULL
.	NULL

Values	NULL
are	NULL
reported	NULL
as	NULL
O.D	NULL
.	NULL

x	NULL
1,000+8D	NULL
(	NULL
n	NULL
=	NULL
4	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Human	NULL
aortic	NULL
valve	NULL
cells	NULL
(	NULL
HAVC	NULL
)	NULL
or	NULL
human	NULL
aortic	NULL
endothelial	NULL
cells	NULL
(	NULL
HAEC	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
no	NULL
additives	NULL
(	NULL
C	NULL
)	NULL
,	NULL
LPS	NULL
(	NULL
L	NULL
)	NULL
,	NULL
or	NULL
MM-LDL	NULL
(	NULL
M	NULL
)	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
RNA	NULL
extracted	NULL
from	NULL
the	NULL
cells	NULL
and	NULL
probed	NULL
for	NULL
MCP-1	NULL
,	NULL
ELAM	NULL
,	NULL
and	NULL
alpha	NULL
tubulin	NULL
.	NULL

All	NULL
other	NULL
conditions	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
described	NULL
for	NULL
other	NULL
Northern	NULL
blot	NULL
analyses	NULL
.	NULL

Duplicate	NULL
lanes	NULL
are	NULL
shown	NULL
for	NULL
each	NULL
condition	NULL
.	NULL

such	NULL
as	NULL
CT.	NULL
Incubation	NULL
of	NULL
RAEC	NULL
with	NULL
3	NULL
ng/ml	NULL
LPS	NULL
for	NULL
4	NULL
h	NULL
increased	NULL
HL60	NULL
and	NULL
monocyte	NULL
binding	NULL
to	NULL
endothelial	NULL
cells	NULL
13-and	NULL
9-fold	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Incubation	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
400	NULL
ng/ml	NULL
CT	NULL
and	NULL
0.5	NULL
mM	NULL
IBMX	NULL
for	NULL
2	NULL
h	NULL
followed	NULL
by	NULL
4	NULL
h	NULL
of	NULL
incubation	NULL
with	NULL
3	NULL
ng/ml	NULL
LPS	NULL
significantly	NULL
inhibited	NULL
the	NULL
induction	NULL
of	NULL
HL60	NULL
but	NULL
not	NULL
monocyte	NULL
binding	NULL
by	NULL
LPS	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Such	NULL
inhibition	NULL
of	NULL
the	NULL
induction	NULL
of	NULL
HL60	NULL
and	NULL
not	NULL
monocyte	NULL
binding	NULL
by	NULL
LPS	NULL
was	NULL
also	NULL
seen	NULL
after	NULL
pretreatment	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
MM-LDL	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Discussion	NULL
Exposure	NULL
of	NULL
endothelial	NULL
cells	NULL
to	NULL
MM-LDL	NULL
leads	NULL
to	NULL
increased	NULL
monocyte	NULL
but	NULL
not	NULL
neutrophil	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
mRNA	NULL
levels	NULL
for	NULL
MCP-1	NULL
and	NULL
M-CSF	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
A	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
pattern	NULL
of	NULL
leukocyte	NULL
binding	NULL
and	NULL
mRNA	NULL
induction	NULL
by	NULL
MM-LDL	NULL
is	NULL
distinct	NULL
from	NULL
that	NULL
of	NULL
other	NULL
inflammatory	NULL
agents	NULL
,	NULL
we	NULL
suspected	NULL
the	NULL
signaling	NULL
pathways	NULL
might	NULL
be	NULL
different	NULL
.	NULL

A	NULL
number	NULL
of	NULL
studies	NULL
have	NULL
concluded	NULL
that	NULL
PKC	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
signal	NULL
transduction	NULL
pathways	NULL
initiated	NULL
by	NULL
thrombin	NULL
,	NULL
TNF-a	NULL
,	NULL
IL-1	NULL
,	NULL
and	NULL
LPS	NULL
(	NULL
9	NULL
,	NULL
16	NULL
)	NULL
.	NULL

PMA	NULL
pretreatment	NULL
of	NULL
endothelial	NULL
cells	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
deplete	NULL
the	NULL
cellular	NULL
content	NULL
of	NULL
PKC	NULL
(	NULL
43	NULL
)	NULL
,	NULL
down-regulated	NULL
the	NULL
monocyte	NULL
binding	NULL
induced	NULL
by	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
4	NULL
)	NULL
but	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
MM-LDL-induced	NULL
monocyte	NULL
binding	NULL
or	NULL
the	NULL
MM-LDL-mediated	NULL
increase	NULL
in	NULL
M-CSF	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
,	NULL
supporting	NULL
the	NULL
conclusion	NULL
that	NULL
PKC	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
these	NULL
MM-LDL-induced	NULL
Inflammatory	NULL
Responses	NULL
Are	NULL
Mediated	NULL
by	NULL
cAMP	NULL
__	NULL
475	NULL
100	NULL
7	NULL
MONO	NULL
F4	NULL
HL6o	NULL
S	NULL
Ss	NULL
80	NULL
60	NULL
CELLS/HPF	NULL
40	NULL
P	NULL
P	NULL
20	NULL
1	NULL
SO	NULL
S	NULL
0+	NULL
Figure	NULL
6	NULL
.	NULL

Effect	NULL
of	NULL
cholera	NULL
toxin	NULL
and	NULL
MM-LDL	NULL
on	NULL
induction	NULL
of	NULL
neutrophil	NULL
and	NULL
monocyte	NULL
binding	NULL
to	NULL
endothelial	NULL
cells	NULL
by	NULL
LPS	NULL
.	NULL

RAEC	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
or	NULL
without	NULL
cholera	NULL
toxin	NULL
(	NULL
CT	NULL
)	NULL
400	NULL
ng/ml	NULL
,	NULL
or	NULL
MM-LDL	NULL
125	NULL
ug/ml	NULL
(	NULL
Mf	NULL
)	NULL
in	NULL
presence	NULL
of	NULL
0.2	NULL
mM	NULL
IBMX	NULL
,	NULL
followed	NULL
by	NULL
4	NULL
h	NULL
incubation	NULL
with	NULL
no	NULL
additives	NULL
(	NULL
C	NULL
)	NULL
or	NULL
LPS	NULL
1	NULL
ng/ml	NULL
(	NULL
L	NULL
)	NULL
.	NULL

Leukocyte	NULL
adhesion	NULL
assay	NULL
was	NULL
performed	NULL
using	NULL
HL60	NULL
and	NULL
monocytes	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
out	NULL
of	NULL
three	NULL
experiments	NULL
and	NULL
the	NULL
values	NULL
from	NULL
a	NULL
representative	NULL
experiment	NULL
are	NULL
reported	NULL
as	NULL
the	NULL
mean	NULL
number	NULL
of	NULL
cells	NULL
bound	NULL
per	NULL
high	NULL
power	NULL
field	NULL
+SEM	NULL
(	NULL
n=	NULL
9	NULL
)	NULL
.	NULL

cellular	NULL
responses	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
that	NULL
,	NULL
in	NULL
fibroblasts	NULL
,	NULL
the	NULL
increase	NULL
of	NULL
mRNA	NULL
levels	NULL
for	NULL
JE	NULL
,	NULL
the	NULL
murine	NULL
homologue	NULL
of	NULL
MCP-1	NULL
gene	NULL
(	NULL
44	NULL
)	NULL
,	NULL
by	NULL
MM-LDL	NULL
is	NULL
PKC	NULL
independent	NULL
.	NULL

Another	NULL
second	NULL
messenger	NULL
that	NULL
mediates	NULL
agonist-induced	NULL
cellular	NULL
responses	NULL
is	NULL
cAMP	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
cAMP	NULL
levels	NULL
mediate	NULL
endothelial	NULL
barrier	NULL
properties	NULL
(	NULL
45	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
endothelium-dependent	NULL
relaxations	NULL
in	NULL
response	NULL
to	NULL
thrombin	NULL
,	NULL
serotonin	NULL
,	NULL
and	NULL
UK14304	NULL
(	NULL
a	NULL
selective	NULL
a	NULL
;	NULL
-adrenergic	NULL
receptor	NULL
agonist	NULL
)	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Of	NULL
relevance	NULL
to	NULL
the	NULL
present	NULL
report	NULL
is	NULL
the	NULL
observation	NULL
by	NULL
Sung	NULL
et	NULL
al	NULL
.	NULL

(	NULL
26	NULL
)	NULL
that	NULL
CT	NULL
treatment	NULL
of	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cells	NULL
induced	NULL
adhesion	NULL
of	NULL
U937	NULL
monocytic	NULL
cells	NULL
to	NULL
endothelial	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
present	NULL
data	NULL
strongly	NULL
suggesting	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
MM-LDL	NULL
prepared	NULL
by	NULL
enzymatic	NULL
modification	NULL
or	NULL
mild	NULL
iron	NULL
oxidation	NULL
are	NULL
mediated	NULL
by	NULL
cAMP	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
incubation	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
MM-LDL	NULL
increased	NULL
the	NULL
levels	NULL
of	NULL
intracellular	NULL
cAMP	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

The	NULL
responses	NULL
induced	NULL
by	NULL
CT	NULL
and	NULL
PT	NULL
,	NULL
both	NULL
of	NULL
which	NULL
caused	NULL
elevation	NULL
of	NULL
cAMP	NULL
levels	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
and	NULL
dbcAMP	NULL
itself	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
induced	NULL
by	NULL
MM-LDL	NULL
.	NULL

These	NULL
responses	NULL
included	NULL
increased	NULL
monocyte	NULL
but	NULL
not	NULL
HL60	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
and	NULL
increased	NULL
levels	NULL
of	NULL
mRNA	NULL
for	NULL
MCP-1	NULL
and	NULL
M-CSF	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
additive	NULL
effect	NULL
of	NULL
MM-LDL	NULL
plus	NULL
CT	NULL
or	NULL
PT	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
these	NULL
agents	NULL
may	NULL
act	NULL
via	NULL
the	NULL
same	NULL
mechanism	NULL
as	NULL
MM-LDL	NULL
.	NULL

Furthermore	NULL
,	NULL
IP	NULL
elevated	NULL
cAMP	NULL
levels	NULL
in	NULL
endothelial	NULL
cells	NULL
,	NULL
increased	NULL
monocyte	NULL
but	NULL
not	NULL
HL6O0	NULL
binding	NULL
,	NULL
and	NULL
increased	NULL
M-CSF	NULL
mRNA	NULL
level	NULL
.	NULL

Native	NULL
LDL	NULL
,	NULL
MDA-LDL	NULL
,	NULL
highly	NULL
oxidized	NULL
LDL	NULL
,	NULL
and	NULL
LPC	NULL
did	NULL
not	NULL
increase	NULL
cAMP	NULL
levels	NULL
and	NULL
did	NULL
not	NULL
induce	NULL
the	NULL
cellular	NULL
responses	NULL
to	NULL
MM-LDL	NULL
reported	NULL
in	NULL
the	NULL
present	NULL
study	NULL
.	NULL

The	NULL
results	NULL
of	NULL
our	NULL
studies	NULL
give	NULL
some	NULL
insight	NULL
into	NULL
the	NULL
possible	NULL
mechanisms	NULL
by	NULL
which	NULL
MM-LDL	NULL
increases	NULL
cAMP	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
both	NULL
CT	NULL
and	NULL
PT	NULL
mimic	NULL
the	NULL
effects	NULL
of	NULL
MM-LDL	NULL
suggests	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
cAMP	NULL
concentration	NULL
by	NULL
MM-LDL	NULL
may	NULL
A476	NULL
-	NULL
Parhami	NULL
,	NULL
Fang	NULL
,	NULL
Fogelman	NULL
,	NULL
Andalibi	NULL
,	NULL
Territo	NULL
,	NULL
and	NULL
Berliner	NULL
be	NULL
at	NULL
the	NULL
level	NULL
of	NULL
G	NULL
,	NULL
or	NULL
G	NULL
;	NULL
proteins	NULL
.	NULL

A	NULL
significant	NULL
level	NULL
of	NULL
G	NULL
;	NULL
has	NULL
been	NULL
detected	NULL
in	NULL
endothelial	NULL
cells	NULL
(	NULL
47	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
in	NULL
these	NULL
cells	NULL
PT	NULL
increased	NULL
cAMP	NULL
levels	NULL
suggests	NULL
that	NULL
perhaps	NULL
under	NULL
normal	NULL
conditions	NULL
an	NULL
active	NULL
population	NULL
of	NULL
G	NULL
;	NULL
proteins	NULL
may	NULL
regulate	NULL
adenylate	NULL
cyclase	NULL
activity	NULL
in	NULL
aortic	NULL
endothelial	NULL
cells	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
expression	NULL
of	NULL
monocyte-binding	NULL
molecules	NULL
,	NULL
MCP-1	NULL
,	NULL
and	NULL
M-CSF	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
G	NULL
;	NULL
,	NULL
by	NULL
PT	NULL
would	NULL
alleviate	NULL
its	NULL
negative	NULL
effect	NULL
,	NULL
thus	NULL
leading	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
cAMP	NULL
levels	NULL
.	NULL

We	NULL
are	NULL
currently	NULL
in	NULL
the	NULL
process	NULL
of	NULL
characterizing	NULL
the	NULL
active	NULL
lipid	NULL
component	NULL
(	NULL
s	NULL
)	NULL
of	NULL
MM-LDL	NULL
.	NULL

Our	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
neutral	NULL
lipids	NULL
(	NULL
including	NULL
oxidized	NULL
fatty	NULL
acids	NULL
)	NULL
(	NULL
8	NULL
)	NULL
and	NULL
LPC	NULL
(	NULL
current	NULL
study	NULL
)	NULL
are	NULL
not	NULL
responsible	NULL
for	NULL
the	NULL
effects	NULL
of	NULL
MM-LDL	NULL
on	NULL
endothelial	NULL
cells	NULL
after	NULL
4	NULL
h	NULL
of	NULL
treatment	NULL
.	NULL

Our	NULL
past	NULL
and	NULL
ongoing	NULL
studies	NULL
suggest	NULL
that	NULL
the	NULL
active	NULL
lipid	NULL
responsible	NULL
for	NULL
the	NULL
effects	NULL
seen	NULL
at	NULL
4	NULL
h	NULL
is	NULL
an	NULL
oxidized	NULL
phospholipid	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Previous	NULL
reports	NULL
showed	NULL
that	NULL
treatment	NULL
of	NULL
RAEC	NULL
with	NULL
levels	NULL
of	NULL
LPC	NULL
used	NULL
by	NULL
us	NULL
caused	NULL
only	NULL
a	NULL
modest	NULL
(	NULL
1.4-fold	NULL
)	NULL
increase	NULL
in	NULL
monocyte	NULL
binding	NULL
(	NULL
compared	NULL
with	NULL
the	NULL
4-10-fold	NULL
induction	NULL
seen	NULL
with	NULL
MM-LDL	NULL
)	NULL
and	NULL
that	NULL
the	NULL
major	NULL
effect	NULL
of	NULL
LPC	NULL
was	NULL
seen	NULL
after	NULL
24	NULL
h	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Our	NULL
previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
effects	NULL
of	NULL
MM-LDL	NULL
may	NULL
continue	NULL
to	NULL
act	NULL
up	NULL
to	NULL
48	NULL
h	NULL
(	NULL
8	NULL
)	NULL
,	NULL
and	NULL
it	NULL
is	NULL
clearly	NULL
possible	NULL
that	NULL
different	NULL
lipids	NULL
,	NULL
such	NULL
as	NULL
LPC	NULL
,	NULL
or	NULL
lipoxygenase	NULL
prod-ucts	NULL
,	NULL
such	NULL
as	NULL
oxidized	NULL
fatty	NULL
acids	NULL
,	NULL
as	NULL
reported	NULL
by	NULL
others	NULL
to	NULL
be	NULL
active	NULL
in	NULL
monocytes	NULL
(	NULL
49	NULL
)	NULL
,	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
prolonged	NULL
activation	NULL
.	NULL

Since	NULL
an	NULL
NFxB	NULL
binding	NULL
site	NULL
is	NULL
present	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
JE	NULL
(	NULL
50	NULL
)	NULL
and	NULL
M-CSF	NULL
genes	NULL
(	NULL
50a	NULL
)	NULL
,	NULL
and	NULL
cAMP	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
NFx	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
51	NULL
)	NULL
,	NULL
we	NULL
suspected	NULL
that	NULL
NFxB	NULL
may	NULL
also	NULL
be	NULL
associated	NULL
with	NULL
MM-LDL	NULL
regulation	NULL
of	NULL
gene	NULL
transcription	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
treatment	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
MM-LDL	NULL
or	NULL
CT	NULL
causes	NULL
activation	NULL
of	NULL
NF	NULL
«	NULL
B	NULL
,	NULL
whereas	NULL
native	NULL
LDL	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
such	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
4	NULL
and	NULL
B	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
NFB	NULL
activation	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
induction	NULL
of	NULL
cellular	NULL
responses	NULL
to	NULL
increased	NULL
intracellular	NULL
cAMP	NULL
levels	NULL
.	NULL

Our	NULL
investigations	NULL
have	NULL
shown	NULL
,	NULL
however	NULL
,	NULL
that	NULL
not	NULL
all	NULL
genes	NULL
with	NULL
NFxB	NULL
binding	NULL
site	NULL
in	NULL
their	NULL
promoter	NULL
region	NULL
are	NULL
induced	NULL
by	NULL
MM-LDL	NULL
;	NULL
mRNA	NULL
levels	NULL
of	NULL
ELAM	NULL
(	NULL
52	NULL
)	NULL
were	NULL
only	NULL
minimally	NULL
induced	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
B	NULL
)	NULL
.	NULL

We	NULL
have	NULL
further	NULL
shown	NULL
that	NULL
increased	NULL
cAMP	NULL
levels	NULL
induced	NULL
by	NULL
MM-LDL	NULL
or	NULL
CT	NULL
inhibited	NULL
the	NULL
induction	NULL
of	NULL
neutrophil	NULL
and	NULL
not	NULL
monocyte	NULL
binding	NULL
by	NULL
LPS	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
dibutyryl	NULL
cAMP	NULL
and	NULL
forskolin	NULL
suppression	NULL
of	NULL
LPS-induced	NULL
TNF-a	NULL
gene	NULL
expression	NULL
has	NULL
been	NULL
previously	NULL
reported	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Pober	NULL
et	NULL
al	NULL
.	NULL

(	NULL
54	NULL
)	NULL
reported	NULL
that	NULL
increased	NULL
cAMP	NULL
levels	NULL
in	NULL
forskolin-treated	NULL
human	NULL
umbilical	NULL
vein	NULL
endothelial	NULL
cells	NULL
inhibited	NULL
TNF-induced	NULL
ELAM	NULL
expression	NULL
.	NULL

Our	NULL
results	NULL
also	NULL
support	NULL
the	NULL
observation	NULL
by	NULL
Montgomery	NULL
et	NULL
al	NULL
.	NULL

(	NULL
55	NULL
)	NULL
that	NULL
NFxB	NULL
is	NULL
associated	NULL
with	NULL
but	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
ELAM	NULL
message	NULL
induction	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
the	NULL
MM-LDL-induced	NULL
increase	NULL
in	NULL
cAMP	NULL
levels	NULL
inhibits	NULL
ELAM	NULL
expression	NULL
.	NULL

It	NULL
is	NULL
evident	NULL
from	NULL
our	NULL
observations	NULL
that	NULL
the	NULL
increased	NULL
monocyte	NULL
binding	NULL
induced	NULL
by	NULL
MM-LDL	NULL
is	NULL
independent	NULL
of	NULL
ELAM	NULL
since	NULL
MM-LDL	NULL
did	NULL
not	NULL
increase	NULL
ELAM	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
4	NULL
)	NULL
.	NULL

We	NULL
have	NULL
also	NULL
ruled	NULL
out	NULL
VCAM	NULL
and	NULL
ICAM	NULL
in	NULL
contributing	NULL
to	NULL
the	NULL
increased	NULL
monocyte	NULL
binding	NULL
seen	NULL
after	NULL
4	NULL
h	NULL
incubation	NULL
of	NULL
endothelial	NULL
cells	NULL
with	NULL
MM-LDL	NULL
(	NULL
56	NULL
)	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
MM-LDL	NULL
up-regulates	NULL
another	NULL
monocyte	NULL
binding	NULL
molecule	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
which	NULL
is	NULL
mediated	NULL
via	NULL
a	NULL
cAMP-dependent	NULL
pathway	NULL
.	NULL

Further	NULL
characterization	NULL
of	NULL
this	NULL
binding	NULL
molecule	NULL
is	NULL
the	NULL
subject	NULL
of	NULL
separate	NULL
studies	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
cellular	NULL
responses	NULL
to	NULL
MM-LDL	NULL
and	NULL
perhaps	NULL
to	NULL
other	NULL
inducers	NULL
of	NULL
chronic	NULL
inflammatory	NULL
responses	NULL
characterized	NULL
by	NULL
inducing	NULL
monocyte	NULL
but	NULL
not	NULL
neutrophil	NULL
infil-	NULL
tration	NULL
are	NULL
regulated	NULL
by	NULL
cAMP	NULL
.	NULL

In	NULL
fatty	NULL
streak	NULL
lesions	NULL
,	NULL
MM-LDL	NULL
may	NULL
induce	NULL
monocyte	NULL
infiltration	NULL
by	NULL
increasing	NULL
cAMP	NULL
.	NULL

It	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
physiological	NULL
agonists	NULL
of	NULL
beta	NULL
adrenergic	NULL
receptors	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
epinephrine	NULL
and	NULL
norepinephrine	NULL
)	NULL
may	NULL
contribute	NULL
to	NULL
monocyte	NULL
infiltration	NULL
in	NULL
atherogenesis	NULL
and	NULL
perhaps	NULL
to	NULL
other	NULL
inflammatory	NULL
processes	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
the	NULL
second	NULL
mes-senger	NULL
,	NULL
cAMP	NULL
,	NULL
activates	NULL
NFxB	NULL
,	NULL
and	NULL
perhaps	NULL
other	NULL
transcription	NULL
factors	NULL
,	NULL
and	NULL
may	NULL
inhibit	NULL
transcription	NULL
of	NULL
genes	NULL
such	NULL
as	NULL
ELAM	NULL
,	NULL
which	NULL
would	NULL
otherwise	NULL
promote	NULL
neutrophil	NULL
binding	NULL
.	NULL

Acknowledgments	NULL
This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
grants	NULL
HL-30568	NULL
and	NULL
TRDRP	NULL
RT372	NULL
and	NULL
the	NULL
Laubisch	NULL
Fund	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Bevilacqua	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
J.	NULL
S.	NULL
Pober	NULL
,	NULL
M.	NULL
E.	NULL
Wheeler	NULL
,	NULL
R.	NULL
S.	NULL
Cotran	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Gimbrone	NULL
.	NULL

1985	NULL
.	NULL

Interleukin	NULL
1	NULL
acts	NULL
on	NULL
cultured	NULL
human	NULL
vascular	NULL
endothelium	NULL
to	NULL
increase	NULL
the	NULL
adhesion	NULL
of	NULL
polymorphonuclear	NULL
leukocytes	NULL
,	NULL
monocytes	NULL
,	NULL
and	NULL
related	NULL
leukocyte	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

76:2003-2011	NULL
.	NULL

2	NULL
.	NULL

Carlos	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
B.	NULL
R.	NULL
Schwartz	NULL
,	NULL
N.	NULL
L.	NULL
Kovach	NULL
,	NULL
E.	NULL
Yee	NULL
,	NULL
M.	NULL
Rosa	NULL
,	NULL
L.	NULL
Osborn	NULL
,	NULL
G.	NULL
Chi-Rosso	NULL
,	NULL
B.	NULL
Newman	NULL
,	NULL
and	NULL
R.	NULL
Lobb	NULL
.	NULL

1990	NULL
.	NULL

Vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
mediates	NULL
lymphocyte	NULL
adherence	NULL
to	NULL
cytokine-activated	NULL
cultured	NULL
human	NULL
endothelial	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

76:965-970	NULL
.	NULL

3	NULL
.	NULL

Rollins	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
T.	NULL
Yoshimura	NULL
,	NULL
E.	NULL
J.	NULL
Leonard	NULL
,	NULL
and	NULL
J.	NULL
S.	NULL
Pober	NULL
.	NULL

1990	NULL
.	NULL

Cytokine-activated	NULL
human	NULL
endothelial	NULL
cells	NULL
synthesize	NULL
and	NULL
secrete	NULL
a	NULL
monocyte	NULL
che-moattractant	NULL
,	NULL
MCP-1	NULL
/JE	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

136:1229-1233	NULL
.	NULL

4	NULL
.	NULL

Ross	NULL
,	NULL
R.	NULL
1986	NULL
.	NULL

The	NULL
pathogenesis	NULL
of	NULL
atherosclerosis-an	NULL
update	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

314:488-500	NULL
.	NULL

5	NULL
.	NULL

Gerrity	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
H.	NULL
K.	NULL
Naito	NULL
,	NULL
M.	NULL
Richardson	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Schwartz	NULL
.	NULL

1979	NULL
.	NULL

Dietary	NULL
induced	NULL
atherogenesis	NULL
in	NULL
the	NULL
swine	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

95:775-791	NULL
.	NULL

6	NULL
.	NULL

Yla-Herttuala	NULL
,	NULL
S.	NULL
,	NULL
W.	NULL
Palinski	NULL
,	NULL
M.	NULL
E.	NULL
Rosenfeld	NULL
,	NULL
S.	NULL
Parthasarathy	NULL
,	NULL
T.	NULL
E.	NULL
Carew	NULL
,	NULL
S.	NULL
Butler	NULL
,	NULL
J.	NULL
L.	NULL
Witztum	NULL
,	NULL
and	NULL
D.	NULL
Steinberg	NULL
.	NULL

1989	NULL
.	NULL

Evidence	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
oxidatively	NULL
modified	NULL
low	NULL
density	NULL
lipoprotein	NULL
in	NULL
atherosclerotic	NULL
lesions	NULL
of	NULL
rabbit	NULL
and	NULL
man	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

84:1086-1095	NULL
.	NULL

7	NULL
.	NULL

Kita	NULL
,	NULL
T.	NULL
,	NULL
Y.	NULL
Nagano	NULL
,	NULL
M.	NULL
Yokode	NULL
,	NULL
K.	NULL
Ishii	NULL
,	NULL
N.	NULL
Kume	NULL
,	NULL
A.	NULL
Ooshima	NULL
,	NULL
H.	NULL
Yoshida	NULL
,	NULL
and	NULL
C.	NULL
Kawai	NULL
.	NULL

1987	NULL
.	NULL

Probucol	NULL
prevents	NULL
the	NULL
progression	NULL
of	NULL
atherosclerosis	NULL
in	NULL
Watanabe	NULL
heritable	NULL
hyperlipidemic	NULL
rabbit	NULL
,	NULL
an	NULL
animal	NULL
model	NULL
for	NULL
familial	NULL
hypercholerterolemia	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:5928-5931	NULL
.	NULL

8	NULL
.	NULL

Berliner	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
M.	NULL
C.	NULL
Territo	NULL
,	NULL
A.	NULL
Sevanian	NULL
,	NULL
S.	NULL
Ramin	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kim	NULL
,	NULL
B.	NULL
Bam-shad	NULL
,	NULL
M.	NULL
Esterson	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Fogelman	NULL
.	NULL

1990	NULL
.	NULL

Minimally	NULL
modified	NULL
low	NULL
density	NULL
lipoprotein	NULL
stimulates	NULL
monocyte	NULL
endothelial	NULL
interactions	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

85:1260-1266	NULL
.	NULL

9	NULL
.	NULL

Cushing	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Berliner	NULL
,	NULL
A.	NULL
J.	NULL
Valentine	NULL
,	NULL
M.	NULL
C.	NULL
Territo	NULL
,	NULL
M.	NULL
Navab	NULL
,	NULL
F.	NULL
Parhami	NULL
,	NULL
R.	NULL
Gerrity	NULL
,	NULL
C.	NULL
J.	NULL
Schwartz	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Fogelman	NULL
.	NULL

1990	NULL
.	NULL

Minimally	NULL
modified	NULL
low	NULL
density	NULL
lipoprotein	NULL
induces	NULL
monocyte	NULL
chemotactic	NULL
protein	NULL
1	NULL
in	NULL
human	NULL
endothelial	NULL
cells	NULL
and	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

87:5134-5138	NULL
.	NULL

10	NULL
.	NULL

Rajavashisth	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
A.	NULL
Andalibi	NULL
,	NULL
M.	NULL
C.	NULL
Territo	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Berliner	NULL
,	NULL
M.	NULL
Navab	NULL
,	NULL
A.	NULL
M.	NULL
Fogelman	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Lusis	NULL
.	NULL

1990	NULL
.	NULL

Induction	NULL
of	NULL
endothelial	NULL
cell	NULL
expression	NULL
of	NULL
granulocyte	NULL
and	NULL
macrophage	NULL
colony-stimulating	NULL
factors	NULL
by	NULL
modified	NULL
low-density	NULL
lipoproteins	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

344:254-257	NULL
.	NULL

11	NULL
.	NULL

Berliner	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
M.	NULL
C.	NULL
Territo	NULL
,	NULL
L.	NULL
Almada	NULL
,	NULL
A.	NULL
Carter	NULL
,	NULL
E.	NULL
Shafonsky	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Fogelman	NULL
.	NULL

1986	NULL
.	NULL

Monocyte	NULL
chemotactic	NULL
factor	NULL
produced	NULL
by	NULL
large	NULL
vessel	NULL
endothelial	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Arteriosclerosis	NULL
.	NULL

6:254-258	NULL
.	NULL

12	NULL
.	NULL

Liao	NULL
,	NULL
F.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Berliner	NULL
,	NULL
M.	NULL
Mehrabian	NULL
,	NULL
M.	NULL
Navab	NULL
,	NULL
L.	NULL
Demer	NULL
,	NULL
A.	NULL
J.	NULL
Lusis	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Fogelman	NULL
.	NULL

1991	NULL
.	NULL

MM-LDL	NULL
is	NULL
biologically	NULL
active	NULL
in	NULL
vivo	NULL
in	NULL
mice	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

87:2253-2257	NULL
.	NULL

13	NULL
.	NULL

Nelken	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
S.	NULL
R.	NULL
Coughlin	NULL
,	NULL
D.	NULL
Gordon	NULL
,	NULL
and	NULL
J.	NULL
N.	NULL
Wilcox	NULL
.	NULL

1991	NULL
.	NULL

Monocyte	NULL
chemoattractant	NULL
protein-1	NULL
in	NULL
human	NULL
atheromatous	NULL
plaques	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88:1121-1127	NULL
.	NULL

14	NULL
.	NULL

Clinton	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
R.	NULL
Underwood	NULL
,	NULL
L.	NULL
Hayes	NULL
,	NULL
M.	NULL
L.	NULL
Sherman	NULL
,	NULL
D.	NULL
W.	NULL
Kufe	NULL
,	NULL
and	NULL
P.	NULL
Libby	NULL
.	NULL

1992	NULL
.	NULL

Macrophage	NULL
colony-stimulating	NULL
factor	NULL
gene	NULL
expression	NULL
in	NULL
vascular	NULL
cells	NULL
and	NULL
in	NULL
experimental	NULL
and	NULL
human	NULL
atherosclerosis	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

140:301-316	NULL
.	NULL

15	NULL
.	NULL

Yla-Herttuala	NULL
,	NULL
S.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Lipton	NULL
,	NULL
M.	NULL
E.	NULL
Rosenfeld	NULL
,	NULL
T.	NULL
Sarkioja	NULL
,	NULL
T.	NULL
Yoshimura	NULL
,	NULL
E.	NULL
J.	NULL
Leonard	NULL
,	NULL
J.	NULL
L.	NULL
Witztum	NULL
,	NULL
and	NULL
D.	NULL
Steinberg	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
monocyte	NULL
chemoattractant	NULL
protein	NULL
1	NULL
in	NULL
macrophage-rich	NULL
areas	NULL
of	NULL
human	NULL
and	NULL
rabbit	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

88:5252-5256	NULL
.	NULL

16	NULL
.	NULL

Lane	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
G.	NULL
E.	NULL
Lamkin	NULL
,	NULL
and	NULL
E.	NULL
V.	NULL
Wancewicz	NULL
.	NULL

1990	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
inhibitors	NULL
block	NULL
the	NULL
enhanced	NULL
expression	NULL
of	NULL
intercellular	NULL
adhesion	NULL
molecule-1	NULL
on	NULL
endothelial	NULL
cells	NULL
activated	NULL
by	NULL
interleukin-1	NULL
,	NULL
lipopolysaccharide	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

172:1273-1281	NULL
.	NULL

17	NULL
.	NULL

Pohlamn	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
K.	NULL
A.	NULL
Stanness	NULL
,	NULL
P.	NULL
G.	NULL
Beatty	NULL
,	NULL
H.	NULL
D.	NULL
Ochs	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Harlan	NULL
.	NULL

1986	NULL
.	NULL

An	NULL
endothelial	NULL
cell	NULL
surface	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
induced	NULL
in	NULL
vitro	NULL
by	NULL
lipopoly-saccharide	NULL
,	NULL
interleukin	NULL
1	NULL
,	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
increases	NULL
neutrophil	NULL
adherence	NULL
by	NULL
a	NULL
CDw18-dependent	NULL
mechanism	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

136:4548-4553	NULL
.	NULL

18	NULL
.	NULL

Carveth	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
R.	NULL
E.	NULL
Shaddy	NULL
,	NULL
R.	NULL
E.	NULL
Whatley	NULL
,	NULL
T.	NULL
M.	NULL
Macintyre	NULL
,	NULL
S.	NULL
M.	NULL
Prescott	NULL
,	NULL
and	NULL
G.	NULL
A.	NULL
Zimmerman	NULL
.	NULL

1992	NULL
.	NULL

Regulation	NULL
of	NULL
platelet-activating	NULL
factor	NULL
(	NULL
PAF	NULL
)	NULL
synthesis	NULL
and	NULL
PAF-mediated	NULL
neutrophil	NULL
adhesion	NULL
to	NULL
endothelial	NULL
cells	NULL
activated	NULL
by	NULL
thrombin	NULL
.	NULL

Semin	NULL
.	NULL

Thromb	NULL
.	NULL

Hemostasis	NULL
.	NULL

18:126-134	NULL
.	NULL

19	NULL
.	NULL

Dicorleto	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
and	NULL
C.	NULL
A	NULL
.	NULL

De	NULL
La	NULL
Motte	NULL
.	NULL

1989	NULL
.	NULL

Thrombin	NULL
causes	NULL
increased	NULL
monocytic-cell	NULL
adhesion	NULL
to	NULL
endothelial	NULL
cells	NULL
through	NULL
a	NULL
protein	NULL
kinase	NULL
C-depen-dent	NULL
pathway	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

264:71-77	NULL
.	NULL

20	NULL
.	NULL

Reithmann	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
Gierschik	NULL
,	NULL
and	NULL
K.	NULL
H.	NULL
Jacobs	NULL
.	NULL

1990	NULL
.	NULL

Stimulation	NULL
and	NULL
inhibition	NULL
of	NULL
adenylate	NULL
cyclase	NULL
.	NULL

Symp	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL

44:207-224	NULL
.	NULL

21	NULL
.	NULL

Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
molecular	NULL
heterogeneity	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
its	NULL
implications	NULL
for	NULL
cellular	NULL
regulation	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

334:661-665	NULL
.	NULL

22	NULL
.	NULL

Krebs	NULL
,	NULL
E.	NULL
G.	NULL
1989	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
cyclic	NULL
AMP-dependent	NULL
protein	NULL
kinase	NULL
in	NULL
signal	NULL
transduction	NULL
.	NULL

J	NULL
.	NULL

Am	NULL
.	NULL

Med	NULL
.	NULL

Assoc	NULL
.	NULL

262:1815-1818	NULL
.	NULL

23	NULL
.	NULL

Taylor	NULL
,	NULL
C.	NULL
W.	NULL
1990	NULL
.	NULL

The	NULL
role	NULL
of	NULL
G	NULL
proteins	NULL
in	NULL
transmembrane	NULL
signalling	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

272	NULL
:	NULL
1-13	NULL
.	NULL

24	NULL
.	NULL

Collins	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
G.	NULL
Caron	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Lefkowitz	NULL
.	NULL

1992	NULL
.	NULL

From	NULL
ligand	NULL
binding	NULL
to	NULL
gene	NULL
expression	NULL
:	NULL
new	NULL
insights	NULL
into	NULL
the	NULL
regulation	NULL
of	NULL
G-protein-coupled	NULL
recep-tors	NULL
.	NULL

Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

17:37-39	NULL
.	NULL

25	NULL
.	NULL

Moss	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
M.	NULL
Vaughan	NULL
.	NULL

1988	NULL
.	NULL

ADP-rubosylation	NULL
of	NULL
guanyl	NULL
nucleotide-binding	NULL
regulatory	NULL
proteins	NULL
by	NULL
bacterial	NULL
toxins	NULL
.	NULL

Adv	NULL
.	NULL

Enzymol	NULL
.	NULL

Relat	NULL
.	NULL

Areas	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

61:303-379	NULL
.	NULL

26	NULL
.	NULL

Sung	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
J.	NULL
Arleth	NULL
,	NULL
B.	NULL
Storer	NULL
,	NULL
and	NULL
G.	NULL
Z.	NULL
Feuerstein	NULL
.	NULL

1991	NULL
.	NULL

Modulation	NULL
of	NULL
U937	NULL
cell	NULL
adhesion	NULL
to	NULL
vascular	NULL
endothelial	NULL
cells	NULL
by	NULL
cyclic	NULL
AMP	NULL
.	NULL

Life	NULL
Sci	NULL
.	NULL

49:375-382	NULL
.	NULL

27	NULL
.	NULL

Oishi	NULL
,	NULL
K.	NULL
,	NULL
R.	NULL
L.	NULL
Raynor	NULL
,	NULL
P.	NULL
A.	NULL
Charp	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Kuo	NULL
.	NULL

1988	NULL
.	NULL

Regulation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
by	NULL
lysophospholipids	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:6865-6871	NULL
.	NULL

28	NULL
.	NULL

O'Brian	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
N.	NULL
E.	NULL
Ward	NULL
,	NULL
I	NULL
.	NULL

B.	NULL
Weinstein	NULL
,	NULL
A.	NULL
W.	NULL
Bull	NULL
,	NULL
and	NULL
L.	NULL
J.	NULL
Marnett	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
rat	NULL
brain	NULL
protein	NULL
kinase	NULL
C	NULL
by	NULL
lipid	NULL
oxidation	NULL
products	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

155:1374-1380	NULL
.	NULL

29	NULL
.	NULL

Laychock	NULL
,	NULL
S.	NULL
G.	NULL
1989	NULL
.	NULL

Coordinate	NULL
interaction	NULL
of	NULL
cyclic	NULL
nucleotide	NULL
and	NULL
phospholipid	NULL
metabolizing	NULL
pathways	NULL
in	NULL
calcium-dependent	NULL
cellular	NULL
responses	NULL
.	NULL

Curr	NULL
.	NULL

Topics	NULL
Cell	NULL
.	NULL

Regul	NULL
.	NULL

30:203-242	NULL
.	NULL

30	NULL
.	NULL

Engelhard	NULL
,	NULL
V.	NULL
H.	NULL
,	NULL
J.	NULL
D.	NULL
Esko	NULL
,	NULL
D.	NULL
R.	NULL
Storm	NULL
,	NULL
and	NULL
M.	NULL
Glaser	NULL
.	NULL

1976	NULL
.	NULL

Modification	NULL
of	NULL
adenylate	NULL
cyclase	NULL
activity	NULL
in	NULL
LM	NULL
cells	NULL
by	NULL
manipulation	NULL
of	NULL
membrane	NULL
phospholipid	NULL
composition	NULL
in	NULL
vivo	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

73:4482-4486	NULL
.	NULL

31	NULL
.	NULL

Gosh	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Activation	NULL
of	NULL
NFKB	NULL
by	NULL
phosphorylation	NULL
of	NULL
its	NULL
inhibitor	NULL
IkB	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

344:678-682	NULL
.	NULL

32	NULL
.	NULL

Shirakawa	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
S.	NULL
B.	NULL
Mizel	NULL
.	NULL

1989	NULL
.	NULL

In	NULL
vitro	NULL
activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-kappa	NULL
B	NULL
catalyzed	NULL
by	NULL
cyclic	NULL
AMP-dependent	NULL
protein	NULL
kinase	NULL
and	NULL
protein	NULL
kinase	NULL
C.	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:2424-2430	NULL
.	NULL

33	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

IkB	NULL
:	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
the	NULL
NF-kB	NULL
transcription	NULL
factor	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

242:540-546	NULL
.	NULL

34	NULL
.	NULL

Sparrow	NULL
,	NULL
C.	NULL
P.	NULL
,	NULL
S.	NULL
Parthasarathy	NULL
,	NULL
and	NULL
D.	NULL
Steinberg	NULL
.	NULL

1988	NULL
.	NULL

Enzymatic	NULL
modification	NULL
of	NULL
low	NULL
density	NULL
lipoprotein	NULL
by	NULL
purified	NULL
lipoxygenase	NULL
plus	NULL
phospholipase	NULL
A	NULL
;	NULL
mimics	NULL
cell-mediated	NULL
oxidative	NULL
modification	NULL
.	NULL

J.	NULL
Lipid	NULL
Res	NULL
.	NULL

29:745-753	NULL
.	NULL

35	NULL
.	NULL

Kosugi	NULL
,	NULL
K.	NULL
,	NULL
D.	NULL
C.	NULL
Morel	NULL
,	NULL
P.	NULL
E.	NULL
DiCorleto	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Chisolm	NULL
.	NULL

1987	NULL
.	NULL

Toxicity	NULL
of	NULL
oxidized	NULL
LDL	NULL
to	NULL
cultured	NULL
fibroblasts	NULL
is	NULL
selective	NULL
for	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Physiol	NULL
.	NULL

130:311~320	NULL
.	NULL

36	NULL
.	NULL

Hoff	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
E.	NULL
Whitaker	NULL
,	NULL
and	NULL
J.	NULL
O'Neil	NULL
.	NULL

1992	NULL
.	NULL

Oxidation	NULL
of	NULL
LDL	NULL
leads	NULL
to	NULL
particulate	NULL
aggregation	NULL
and	NULL
altered	NULL
macrophage	NULL
recognition	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:602-609	NULL
.	NULL

37	NULL
.	NULL

Steinbrecher	NULL
,	NULL
U.	NULL
P.	NULL
1987	NULL
.	NULL

Oxidation	NULL
of	NULL
human	NULL
LDL	NULL
results	NULL
in	NULL
derivatiza-tion	NULL
of	NULL
lysine	NULL
residues	NULL
of	NULL
apolipoprotein	NULL
B	NULL
by	NULL
lipid	NULL
peroxide	NULL
decomposition	NULL
products	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262:3603-3608	NULL
.	NULL

38	NULL
.	NULL

Fogelman	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
I.	NULL
Schechter	NULL
,	NULL
J.	NULL
Seager	NULL
,	NULL
M.	NULL
Hokam	NULL
,	NULL
J.	NULL
S.	NULL
Child	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Edwards	NULL
.	NULL

1980	NULL
.	NULL

Malondialdehyde	NULL
alteration	NULL
of	NULL
LDL	NULL
leads	NULL
to	NULL
cholesteryl	NULL
ester	NULL
accumulation	NULL
in	NULL
human	NULL
monocyte	NULL
macrophages	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

77:2214-2218	NULL
.	NULL

39	NULL
.	NULL

Chomczynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
N.	NULL
Sacchi	NULL
.	NULL

1987	NULL
.	NULL

Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acid	NULL
guanidinium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

162:156-159	NULL
.	NULL

40	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
kappa	NULL
B.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

86:2336-2340	NULL
.	NULL

41	NULL
.	NULL

Mattila	NULL
,	NULL
P.	NULL
1991	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
subtypes	NULL
in	NULL
endothelial	NULL
cells	NULL
.	NULL

FEBS	NULL
(	NULL
Fed	NULL
.	NULL

Eur	NULL
.	NULL

Biochem	NULL
.	NULL

Soc	NULL
.	NULL
)	NULL

Lett	NULL
.	NULL

289:86-90	NULL
.	NULL

42	NULL
,	NULL
Luscinskas	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
A.	NULL
F.	NULL
Brock	NULL
,	NULL
M.	NULL
A.	NULL
Arnaout	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Gimbrone	NULL
.	NULL

1989	NULL
.	NULL

Endothelial-leukocyte	NULL
adhesion	NULL
molecule-l-dependent	NULL
and	NULL
leukocyte	NULL
(	NULL
CD11/CD18	NULL
)	NULL
-dependent	NULL
mechanisms	NULL
contribute	NULL
to	NULL
polymorphonuclear	NULL
leukocyte	NULL
adhesion	NULL
to	NULL
cytokine-activated	NULL
human	NULL
vascular	NULL
endothelium	NULL
.	NULL

J.	NULL
immunol	NULL
.	NULL

142:2257-2263	NULL
.	NULL

43	NULL
.	NULL

Young	NULL
,	NULL
S.	NULL
,	NULL
P.	NULL
J.	NULL
Parker	NULL
,	NULL
A.	NULL
Ullrich	NULL
,	NULL
and	NULL
S.	NULL
Stabel	NULL
.	NULL

1987	NULL
.	NULL

Down-regulation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
is	NULL
due	NULL
to	NULL
an	NULL
increased	NULL
rate	NULL
of	NULL
degradation	NULL
.	NULL

Biochem	NULL
.	NULL

J	NULL
.	NULL

244:775-779	NULL
.	NULL

44	NULL
.	NULL

Bork	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
K.	NULL
L.	NULL
Svenson	NULL
,	NULL
M.	NULL
Mehrabian	NULL
,	NULL
A.	NULL
J.	NULL
Lusis	NULL
,	NULL
A.	NULL
M.	NULL
Fogelman	NULL
,	NULL
MM-LDL-induced	NULL
Inflammatory	NULL
Responses	NULL
Are	NULL
Mediated	NULL
by	NULL
cAMP	NULL
__	NULL
477	NULL
and	NULL
P.	NULL
A.	NULL
Edwards	NULL
.	NULL

1992	NULL
.	NULL

Mechanisms	NULL
controlling	NULL
competence	NULL
gene	NULL
expression	NULL
in	NULL
murine	NULL
fibroblasts	NULL
stimulated	NULL
with	NULL
MM-LDL	NULL
.	NULL

Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

12:800-806	NULL
.	NULL

45	NULL
.	NULL

Stelzner	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
J.	NULL
V.	NULL
Weil	NULL
,	NULL
and	NULL
R.	NULL
F.	NULL
O'brien	NULL
.	NULL

1989	NULL
.	NULL

Role	NULL
of	NULL
cyclic	NULL
adenosine	NULL
monophosphate	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
endothelial	NULL
barrier	NULL
properties	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Physiol	NULL
.	NULL

139:157-166	NULL
.	NULL

46	NULL
.	NULL

Shimokawa	NULL
,	NULL
H.	NULL
,	NULL
N.	NULL
A.	NULL
Flavahan	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Vanhoutte	NULL
.	NULL

1991	NULL
.	NULL

Loss	NULL
of	NULL
endothelial	NULL
pertussis	NULL
toxin-sensitive	NULL
G	NULL
protein	NULL
function	NULL
in	NULL
atherosclerotic	NULL
porcine	NULL
coronary	NULL
arteries	NULL
.	NULL

Circulation	NULL
.	NULL

83:652-660	NULL
.	NULL

47	NULL
.	NULL

Flavahan	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Vanhoutte	NULL
.	NULL

1990	NULL
.	NULL

G-protein	NULL
and	NULL
endothelial	NULL
responses	NULL
.	NULL

Blood	NULL
Vessels	NULL
.	NULL

27:218-229	NULL
.	NULL

48	NULL
.	NULL

Kume	NULL
,	NULL
N.	NULL
,	NULL
M.	NULL
I.	NULL
Cybulsky	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Gimbrone	NULL
,	NULL
Jr.	NULL
1992	NULL
.	NULL

Lysophosphati-dylcholine	NULL
,	NULL
a	NULL
component	NULL
of	NULL
atherogenic	NULL
lipoproteins	NULL
,	NULL
induces	NULL
mononuclear	NULL
leukocyte	NULL
adhesion	NULL
molecules	NULL
in	NULL
cultured	NULL
human	NULL
and	NULL
rabbit	NULL
endothelial	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

90:1138-1	NULL
144	NULL
.	NULL

49	NULL
.	NULL

Ku	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
L.	NULL
Akeson	NULL
,	NULL
M.	NULL
Mano	NULL
,	NULL
C.	NULL
E.	NULL
Thomas	NULL
,	NULL
and	NULL
R.	NULL
L.	NULL
Jackson	NULL
.	NULL

1991	NULL
.	NULL

Products	NULL
of	NULL
oxidized	NULL
linoleate	NULL
mediate	NULL
macrophage	NULL
cytokine	NULL
release	NULL
and	NULL
smooth	NULL
muscle	NULL
cell	NULL
proliferation	NULL
.	NULL

Clin	NULL
.	NULL

Res	NULL
.	NULL

39:3355-3359	NULL
.	NULL

50	NULL
.	NULL

Visvanathan	NULL
,	NULL
K.	NULL
V.	NULL
,	NULL
and	NULL
S.	NULL
Goodbourn	NULL
.	NULL

1989	NULL
.	NULL

Double-stranded	NULL
RNA	NULL
activates	NULL
binding	NULL
of	NULL
NF-kappa	NULL
B	NULL
to	NULL
an	NULL
inducible	NULL
element	NULL
in	NULL
the	NULL
human	NULL
beta-inter-feron	NULL
promoter	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

$	NULL
:1129-1138	NULL
.	NULL

50a.Rajavashisth	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
K.	NULL
Doan	NULL
,	NULL
and	NULL
J.	NULL
Mechta	NULL
.	NULL

1993	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
binding	NULL
cis-DNA	NULL
elements	NULL
mediate	NULL
transcriptional	NULL
activation	NULL
of	NULL
M-CSF	NULL
gene	NULL
by	NULL
minimally	NULL
modified	NULL
LDL	NULL
.	NULL

FASEB	NULL
(	NULL
Fed	NULL
.	NULL

Am	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL
)	NULL

J.	NULL
T	NULL
:	NULL
A341	NULL
.	NULL

(	NULL
Abstr	NULL
.	NULL

1976	NULL
)	NULL
.	NULL

51	NULL
.	NULL

Shirakawa	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
Chedid	NULL
,	NULL
J.	NULL
Suttles	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Pollok	NULL
,	NULL
and	NULL
S.	NULL
B.	NULL
Mizel	NULL
.	NULL

1989	NULL
.	NULL

478	NULL
-	NULL
Parhami	NULL
,	NULL
Fang	NULL
,	NULL
Fogelman	NULL
,	NULL
Andalibi	NULL
,	NULL
Territo	NULL
,	NULL
and	NULL
Berliner	NULL
Interleukin	NULL
1	NULL
and	NULL
cyclic	NULL
AMP	NULL
induce	NULL
kappa	NULL
immunoglobulin	NULL
light-chain	NULL
expres	NULL
sion	NULL
via	NULL
activation	NULL
of	NULL
an	NULL
NF-kappa	NULL
B-like	NULL
DNA-binding	NULL
protein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:959-964	NULL
.	NULL

52	NULL
.	NULL

Collins	NULL
,	NULL
T.	NULL
,	NULL
A.	NULL
Williams	NULL
,	NULL
G.	NULL
I.	NULL
Johnston	NULL
,	NULL
J.	NULL
Kim	NULL
,	NULL
R.	NULL
Eddy	NULL
,	NULL
T.	NULL
Shows	NULL
,	NULL
M.	NULL
A.	NULL
Gimbrone	NULL
,	NULL
and	NULL
M.	NULL
P.	NULL
Bevilacqua	NULL
.	NULL

1991	NULL
.	NULL

Structure	NULL
and	NULL
chromosomal	NULL
location	NULL
of	NULL
the	NULL
gene	NULL
for	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule	NULL
1	NULL
.	NULL

J.	NULL
Bio	NULL
!	NULL

Chem	NULL
.	NULL

266:2466-2473	NULL
.	NULL

53	NULL
.	NULL

Spengler	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
M.	NULL
L.	NULL
Spengler	NULL
,	NULL
P.	NULL
Lincoln	NULL
,	NULL
D.	NULL
G.	NULL
Remick	NULL
,	NULL
R.	NULL
M.	NULL
Strieter	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
Kunkel	NULL
.	NULL

1989	NULL
.	NULL

Dynamics	NULL
of	NULL
dibutyryl	NULL
cyclic	NULL
AMP-	NULL
and	NULL
prostaglandin	NULL
E2-mediated	NULL
suppression	NULL
of	NULL
lipopolysaccharide-induced	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
gene	NULL
expression	NULL
.	NULL

Infect	NULL
.	NULL

Immun	NULL
.	NULL

57:2837-2841	NULL
.	NULL

54	NULL
.	NULL

Pober	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
M.	NULL
Slowik	NULL
,	NULL
L.	NULL
Deluco	NULL
,	NULL
and	NULL
A.	NULL
J.	NULL
Ritchie	NULL
.	NULL

1992	NULL
.	NULL

Elevated	NULL
cAMP	NULL
inhibits	NULL
endothelial	NULL
expression	NULL
of	NULL
ELAM-1	NULL
and	NULL
VCAM-1	NULL
but	NULL
not	NULL
ICAM-1	NULL
.	NULL

FASEB	NULL
(	NULL
Fed	NULL
.	NULL

Am	NULL
.	NULL

Soc	NULL
.	NULL

Exp	NULL
.	NULL

Biol	NULL
.	NULL
)	NULL

J	NULL
.	NULL

6	NULL
:	NULL
A1592	NULL
.	NULL

55	NULL
.	NULL

Montgomery	NULL
,	NULL
K.	NULL
F.	NULL
,	NULL
L.	NULL
Osborn	NULL
,	NULL
C.	NULL
Hession	NULL
,	NULL
R.	NULL
Tizard	NULL
,	NULL
D.	NULL
Goff	NULL
,	NULL
C.	NULL
Vas-sallo	NULL
,	NULL
P.	NULL
I.	NULL
Tarr	NULL
,	NULL
K.	NULL
Bomsztyk	NULL
,	NULL
R.	NULL
Lobb	NULL
,	NULL
J.	NULL
M.	NULL
Harlan	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
.	NULL

Activation	NULL
of	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule	NULL
1	NULL
(	NULL
ELAM-1	NULL
)	NULL
gene	NULL
transcription	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

88:6523-6527	NULL
.	NULL

56	NULL
.	NULL

Berliner	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
D.	NULL
S.	NULL
Schwartz	NULL
,	NULL
M.	NULL
C.	NULL
Territo	NULL
,	NULL
A.	NULL
Andalibi	NULL
,	NULL
L.	NULL
Almada	NULL
,	NULL
A.	NULL
J.	NULL
Lusis	NULL
,	NULL
D.	NULL
Quismorio	NULL
,	NULL
Z.	NULL
T.	NULL
Fang	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Fogelman	NULL
.	NULL

Induction	NULL
of	NULL
chemotactic	NULL
cytokines	NULL
by	NULL
MM-LDL	NULL
.	NULL

In	NULL
Chemotactic	NULL
Cytokines	NULL
4	NULL
.	NULL

Springer	NULL
Verlag	NULL
,	NULL
New	NULL
York	NULL
.	NULL

In	NULL
press	NULL
.	NULL

57	NULL
.	NULL

Bevilacqua	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
J.	NULL
S.	NULL
Pober	NULL
,	NULL
D.	NULL
L.	NULL
Mendrick	NULL
,	NULL
R.	NULL
S.	NULL
Cotran	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Jimbrone	NULL
.	NULL

1987	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
inducible	NULL
endothelial-leukocyte	NULL
adhesion	NULL
molecule	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

84:9238-9242	NULL
.	NULL

